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Review
Acquired Resilience: An Evolved System
of Tissue Protection in Mammals
Jonathan Stone1, John Mitrofanis2, Daniel M. Johnstone1,
Benedetto Falsini3, Silvia Bisti4, Paul Adam5, Arturo Bravo Nuevo6,
Mindy George-Weinstein6, Rebecca Mason1, and Janis Eells7
Abstract
This review brings together observations on the stress-induced regulation of resilience mechanisms in body tissues. It is argued
that the stresses that induce tissue resilience in mammals arise from everyday sources: sunlight, food, lack of food, hypoxia and
physical stresses. At low levels, these stresses induce an organised protective response in probably all tissues; and, at some higher
level, cause tissue destruction. This pattern of response to stress is well known to toxicologists, who have termed it hormesis.
The phenotypes of resilience are diverse and reports of stress-induced resilience are to be found in journals of neuroscience,
sports medicine, cancer, healthy ageing, dementia, parkinsonism, ophthalmology and more. This diversity makes the proposing of
a general concept of induced resilience a significant task, which this review attempts. We suggest that a system of stress-induced
tissue resilience has evolved to enhance the survival of animals. By analogy with acquired immunity, we term this system ‘acquired
resilience’. Evidence is reviewed that acquired resilience, like acquired immunity, fades with age. This fading is, we suggest, a major
component of ageing. Understanding of acquired resilience may, we argue, open pathways for the maintenance of good health in
the later decades of human life.
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. . . it was too marvellous and gave rise to skepticism
Niels Finsen,1 Nobel Laureate (1903), recalling criticism of
his evidence that red light accelerated the healing of the skin
lesions of smallpox.
Outline
This review brings together a range of observations on the
stress-induced regulation of self-protective/self-repair mechan-
isms in body tissues. It is argued that the stresses that induce
tissue resilience in mammals arise from several everyday
sources:
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 sunlight (UV, visible light, infrared, X-rays);
 food—the toxins of ordinary food;
 lack of food: hunger and caloric restriction;
 hypoxia of a tissue caused by:
 blockage or hemorrhage of vessels supplying the
tissue (ischemia),
 ischemia of distant tissues (remote ischemia),
 rapid increases in oxygen consumption (particularly
exercise);
 experimental or altitude hypoxia;
 physical stresses:
 heat, cold,
 mechanical damage,
 the stress of blood flow on vessel endothelium.
At low levels, these stresses induce an organized protective
response in probably all tissues and, at some higher level, cause
tissue destruction. This low-dose-resilience/high-dose-toxic
pattern of response to stress is well known to toxicologists,
who have termed it hormesis.
The phenotype of the resilience induced by low-dose stress
often depends on the investigators’ interest. Studies have
reported that low-dose stress induces:
 The acceleration of wound healing;
 Conditioning of undamaged tissue, making it resilient in
the face of subsequent stress;
 Slowing or stopping age-related degenerations of central
nervous tissue (Parkinson, Alzheimer, macular degen-
eration), of connective tissue (skin aging), or of muscle
(sarcopenia);
 Reduction of genotoxicity (ie, protection of the gen-
ome), so reduction in the formation of cancers;
 Accelerated reduction of inflammation and pain;
 Supernormal function, reported in muscle and retina;
 Acceleration of recovery from fatigue, reported inmuscle;
 Suppression of cancer, proliferation, and metastasis as
well as mutagenesis.
In relation to aging, investigators have reported 2 major
resilience phenomena:
 Resilience fades with aging; the same stress that induces
resilience in youthful tissue in age no longer induces
resilience.
 Resilience can be maintained into old age, by the same
stresses that induce tissue resilience in the young, best
studied for exercise.
As a consequence, the phenotypes of resilience include:
 Reduction of morbidity, particularly in the elderly
patients, contributing to greater longevity.
Because of this diversity of phenotype, reports of stress-
induced resilience are to be found in journals of neuroscience,
sports medicine, cancer, healthy aging, dementia, parkinsonism,
ophthalmology, and more. The diversity makes the proposing of
a general concept of induced resilience a significant task, which
this review attempts.
The mechanisms by which low-level stress upregulates resi-
lience have been studied intensively. Some are tissue-specific.
The skin and retina, for example, have evolved skin- and retina-
specific responses to daylight. By contrast, ingested plant tox-
ins circulate through the body and induce resilience in probably
all tissues, and exercise, infrared radiation, and caloric restric-
tion also induce body-wide resilience. Further, many stressors
appear to operate by common mechanisms, as their effects do
not sum, and correspondingly, each can induce many, perhaps
all, of the phenotypes of resilience. The “rules” of induced
resilience are still being worked out.
We suggest that a system of stress-induced tissue resilience
has evolved to enhance the survival of animals, which are all
subject to everyday stress. By analogy with acquired immunity,
in which exposure to a pathogen induces immunity, we term
this system, which responds to low-level stresses by upregu-
lated resilience-inducing pathways, “acquired resilience.” And,
having in mind the fading of acquired immunity with age
(immunosenescence), we consider whether a comparable fad-
ing of acquired resilience (resiliosenescence) can be identified
and conclude that it can. The fading of resilience, we argue, is a
major component of the cause of aging, including features of
aging such as sarcopenia, cancer, slowness of wound healing,
slowness in recovery from fatigue, and more. Understanding of
acquired resilience may, we argue, open pathways for the
maintenance of good health in the later decades of human life.
The Stresses That Induce Resilience
When the stresses known to induce tissue resilience are cata-
loged, they fall into groups—sunlight and other radiations,
plant toxins, tissue hypoxia including the hypoxia resulting
from vascular failure, respiratory dysfunction and exercise,
hunger and caloric restriction, and physical stress (heat,
mechanical damage, sheer stress to the vascular endothelium).
These are the everyday stresses of everyday life.
The idea that some level of stress is beneficial has common
currency, for example, in the saying “whatever doesn’t kill me
makesme stronger.” The concept of “eustress,” or good stress,was
developed by psychologists who (naturally enough) discussed it in
psychological terms (eg, the study by O’Sullivan2). The term
allows a useful distinction between eustress and distress, and the
analogy is clear with the low-dose-tonic and high-dose-toxic phe-
nomena of hormesis, discussed below. The forms of stress consid-
ered below arise, however, from physical, chemical, or metabolic
sources and, importantly, their effects have been demonstrated in
subject-blind investigations, so free of psychological influences.
Light and Other Radiations
Sunlight
The radiant energy experienced by animals arises almost entirely
from the sun. The idea that sunlight has health-giving properties
2 Dose-Response: An International Journal
goes back to early traditions of medicine; histories of light as
therapy can be found elsewhere.3-8 The transition from anec-
dotes, traditions, and clinical impressions to testable hypotheses
of the curative potential of sunlight took a major step with the
work of Niels Finsen1,9,10 (see also https://www.nobelprize.org/
nobel_prizes/medicine/laureates/1903/) who reported healing
effects of UV light for the skin lesions of tuberculosis and of
red light for the skin lesions of smallpox. With Finsen’s work,
recognized by the 1903 Nobel Prize, and the work of his con-
temporaries, the idea that sunlight can enhance the resilience of
body tissues entered the peer-reviewed literature. A century and
more later, thousands of peer-reviewed studies give evidence
that many wavelengths within sunlight can, at appropriate low
doses, induce tissue resilience.
Red–Infrared Light (600-1000 nm)
The fight against the disease smallpox had a major impact on
medical science, leading to the understanding of variolation,
vaccination, cross-immunity, and acquired immunity. The
same fight also led, with a half-century’s delay, to some of our
understanding of tissue resilience.
Physicians in Finsen’s time noted that the skin lesions of
smallpox were most prominent on the arms and face, the areas
most free of clothing. Daylight, physicians inferred, might be
exacerbating these lesions and they prescribed darkness. Finsen
and others—influenced by reports of the value of red swathing
and red curtains, and by the practical need for some lighting—
kept patients in filtered red light rather than darkness. In an
early (1895) meta-analysis, Finsen9 reviewed reports from a
dozen clinics of “the extremely favorable” effect of red light
in the healing of lesions and corresponding reductions in mor-
tality and in the scarring of survivors:
The total number of patients treated (in seven published studies)
was about 70, and the method failed in only one case. It must be
observed that these reports are of considerable value, as the
authors as a rule were evidently exceedingly skeptical . . . .
Some few of them have confined themselves to mere reports
of the history of the cases, and have otherwise been extremely
reserved in their expressions of opinion; some (Feilberg,
Svendsen) have for certainty’s sake made controlling experi-
ments; others (Oettinger, for instance) chose the most severe
cases to experiment with.
Progress was delayed partly by the personal tragedy of Finsen’s
early death, in 1904, and partly because advances in vaccination
in the following decades did much to prevent smallpox. Those
decades saw rapid advances in many areas of medicine, but the
idea of light-inducible tissue resilience was not among them.
Explorationof the concept resumed in the 1960s, stimulated not
by a disease but by a technical advance, the development of
wavelength-specific light sources—lasers and light-emitting
diodes (LEDs).5 Finsen had selected red or UV light from white
light with pigmented filters; now the wavelength and energy of
radiation couldbe engineeredwith precision, and their effectswere
explored systematically. Even so, this new phase of work began
with surprise observations. In one early and influential study,
Mester and colleagues11 set out (for an account see4) to test
whether 694 nm laser light, shone on the shaved skin of mice,
would induce cancer. No cancer formed; instead, they reported the
laser radiation increased hair growth, a finding since confirmed for
low-dose irradiation.12 In a second study (for an account, see the
study by Ga´spa´r13), the same group sought to use the same wave-
length to destroy experimentally implanted tumors. The tumors
seemed unaffected, but the irradiation accelerated the healing of
the implantation wound, a finding extensively confirmed.
Since these early reports, analysis of the resilience induced by
red–infrared light generated by laser sources has advanced from
surprise observation to systematic laboratory studies and rando-
mized clinical trials, on a range of tissues and with effects too
numerous to be summarized readily. The terms “low-level light
therapy” and “photobiomodulation” (PBM) have been adopted
by theUSNational Library ofMedicine as indexing terms for the
induction of positive tissue responses using laser or LED sources
(see https://www.ncbi.nlm.nih.gov/mesh/?%25term¼photobio
modulation). Recent reviews describe present understanding of
the impact of red–infrared light on the resilience of the skin14 and
in inducing supernormal performance inmuscle as well as accel-
erated recovery from fatigue and injury.15,16 The use of PBMas a
neuroprotectant was pioneered by Eells and colleagues17 in a
model of alcohol-induced degeneration of retinal photoreceptors
and has been extended to the slowing of cerebral degenera-
tions,18-24 the mitigation of the effects of traumatic brain
injury,25-30 the mitigation of macular degeneration,31,32 and
improvements in the outcome of stroke.33,34 The value of PBM
for the mitigation of retinal damage in a range of conditions has
received support from a recent meta-analysis5; the author adds
caution that larger scale clinical trials are needed for a fuller
understanding of the mechanisms involved.
Many studies reported trials of different dose regimes; they
report consistently that PBM is effective at low doses, up to
*10 J/cm2/d, and that increasing the daily dosage further leads
to a loss of effect.4 Increasing the number of consecutive days at
which a low dose is given causes a steady increase in effect, at least
up to 10 days.35 But more needs to be known concerning dosage.
One recent open-label, single-arm clinical study36 trialed a course
of 12 doses of relatively high-intensity infrared light directed tran-
scranially at the frontal and temporal lobes, in patients suffering
mild-to-severe depression, reporting robust mitigation of depres-
sion scores,maintained for up to 55months from a single course of
treatment. Side effects were minimal; the authors suggested the
outcome provided a basis for randomly controlled trials.
Mechanisms. The mechanisms of PBM have been reviewed
extensively, with 2 sets of actions emerging, “direct” and
“indirect.” There is strong evidence that PBM induces resili-
ence in tissue directly irradiated and that irradiation at one site
induces resilience body-wide, so indirectly.
In most studies, the tissue under study has been irradiated
directly, whether cells in vitro, or skin wounds, painful joints or
tooth sockets, or the retina. The brain has also been irradiated
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directly, either transcranially or by an optical fiber placed deep
into the brain,37 or by an intranasal probe38 to reach the inferior
surface of the frontal lobe. Only a minority of studies, but still
many, have tested mechanisms of this direct irradiation,
reviewed elsewhere.4,7,39-41 The most easily understood
mechanism of direct irradiation is that the incident light is
absorbed by a photoacceptor in the oxidative phosphorylation
pathway of mitochondria, accelerating the production of ade-
nosine triphosphate (ATP) in injured cells, most clearly demon-
strated in vitro.42 As Hamblin and Demidova4 noted, however,
there is good evidence of more-complex-to-describe actions of
PBM on the tissue irradiated. The PBM may increase the pro-
duction of superoxide ions, shifting the “redox state” of the
cell; it may reverse the inhibition of cytochrome oxidase by
nitric oxide (NO), increasing oxygen-fueled oxidative phos-
phorylation. Further, changes in the redox state regulate a num-
ber of transcription factors; Hamblin and Demidova identified
nuclear factor (NF)-kB, p53, ARG/CREB, and HIF-like factor
as regulated by redox state and therefore potentially by PBM.
Finally, Hamblin and Demidova noted that some tissue
responses to PBM can be described only at the cellular
level—the stimulation of metabolism, migration, proliferation,
and the synthesis and secretion of proteins, including power-
fully trophic proteins such as FGF-2.
A still different and complex picture of the mechanisms of
direct irradiation of tissue emerges when gene array technology
is used. Natoli and colleagues,43 for example, examined gene
regulation induced by direct PBM of retina, both uninjured
retina and retina damaged by bright light (light damage or
LD). Comparing normal retina with LD retina with PBM-
irradiated retina with retina irradiated (conditioned) with PBM
and then damaged by light, we concluded that
. . . PBM, given without LD, changes retinal gene expression in
a significant number of entities, and that, given as a pretreat-
ment to LD, PBM (like saffron) changes the expression of a
large numbers of entities, reducing the LD-induced regulation
of many and regulating many not affected by LD.
PBM, . . . appears to regulate many intracellular pathways when
given as a pretreatment . . . a large proportion of the entities
regulated by PBM are ncRNAs, and further understanding of
the protective action of PBM will require understanding to the
roles of these sequences.
So, to understand the patterns of gene expression that we
observed, we were obliged to distinguish between genes and
noncoding RNAs (ncRNA), the latter still not well understood,
and between the regulation of ncRNA and gene expression
induced by PBM in unstressed (control) tissue, and the mod-
ification by PBM of the extensive changes in gene and ncRNA
expression induced by light-induced damage of the retina. It is
not an outcome easy to summarize, and there have been few
analyses of PBM-induced gene expression in the years since to
take the analysis further. An important element of the analysis
is that PBM regulates many more genes and ncRNAs in injured
tissue than in uninjured tissues. More generally, the description
of the mechanisms of direct PBM varies with the observations
made, and the response is complex, involving multiple path-
ways, influencing many aspects of cell function.
Realization that PBM has indirect effects came from occa-
sional reports as early as 1989, that irradiation of a wound on one
flank of an experimental animal accelerated healing on both
flanks44,45; that irradiation of a crushed sciatic nerve improved
the function of both nerves45; that irradiation localized to a skin
wound at one point on a human arm accelerated healing several
centimeters away46; that irradiating one side of the face of chil-
dren undergoing immunosuppression prior to a bone marrow
transplantation prevented sores forming on both sides47; that,
in mice with gliomas implanted under the skin of the back, PBM
directed at the abdomen inhibited tumor growth.48 These work-
ers all sought to use nonirradiation of one side or part of the body
as a control for irradiation of a wounded site. The controls did
not work as expected and, when the investigators—most clearly
Rochkind and colleagues45—checked why, it became clear that
the effects of PBM are not confined to the tissue irradiated.
Building on these studies, the present authors tested and
confirmed the indirect effect of PBM, showing that irradiation
of the body of a mouse (with the head shielded) protects the
substantia nigra (SNc) of the midbrain (a key locus of the
neuropathology of parkinsonism) from toxin-induced dam-
age.49-52 Further, the protection achieved by irradiation of the
body was less than when both head and body were irradiated.
Our interim conclusion was that PBM protects the SNc by both
direct and indirect mechanisms and that—when both head and
body are irradiated—their effects sum.
A separate line of evidence of the reality and mechanisms of
the indirect action of PBM was developed by Oron and col-
leagues,53-55 who linked a series of observations. First, they
observed that infrared light induces the proliferation of stem cells
in vitro, extending earlier observations of PBM-induced prolif-
eration.55They next showed that the healing of infarcts in rat heart
muscle was accelerated by the implantation of PBM-treated stem
cells harvested from bone marrow54; then that PBM directed at
the bonemarrowwas particularly effective in protecting rat heart
muscle from ischemia,53 adding evidence that the protection was
mediated by bone marrow–derived stem cells, migrating to or
proliferating at the site of ischemia. The same authors have
extended these observations, reporting that PBM directed at the
bonemarrow of the tibia slows the progression of Alzheimer-like
pathology in themouse18,56 and reduces scarring caused by ische-
mia to heart muscle in the pig.57 A third group,58 working in a
mouse model of diabetic retinopathy, used a lead helmet to limit
radiation to the body, showing that PBM irradiation of the body
mitigateddiabetes-induced changes, including leukostasis, super-
oxide generation, and visual performance.
The complexity of mechanisms underlying the indirect action
of PBM has become evident from a line of research on subpo-
pulations of bone marrow–derived stem cells, confirming that as
Oron and colleagues have argued, resident and bone marrow–
derived stem cells promote tissue regeneration and cell viability
and induce angiogenesis in multiple tissues, including the ner-
vous system, retina, and heart (see eg, the study by Muheremu
4 Dose-Response: An International Journal
et al, Bruyneel et al, Ward et al, Marichal et al, and Oner59-63).
One such subpopulation recently shown to be involved in the
resilience response has been dubbed “Myo/Nog cells.” Cells of
this lineage were identified in the early embryo by their expres-
sion of the skeletal muscle-specific transcription factor MyoD
and bone morphogenetic protein inhibitor noggin.64-66 During
development, noggin released by Myo/Nog cells is critical for
normal morphogenesis and skeletal muscle differentiation.64,67
In the embryo and adult, these cells also respond to injury and
cell death in multiple tissues.65-70 For example, in retina dam-
aged by excessive light or hypoxia, Myo/Nog/Nog cells accu-
mulate in areas of cells death.65,66 If the damage to the retina is
mitigated, for example, by PBM or dietary saffron (discussed
below), fewer Myo/Nog cells congregate in the damaged region.
A neuroprotective role for Myo/Nog cells was revealed when
photoreceptor death was reduced and retinal function was
improved in response to injection of brain-derived Myo/Nog
cells into the vitreous humor of the eye.66 And, conversely, in
the retina damaged by hypoxia, the targeted depletion of Myo/
Nog cells resulted in an increase in neuronal cell death.65
This multipotency is, of course, what stems cells are about.
But this evidence that Myo/Nog cells adopt new roles during
the lifetime of mammals (they have been observed in mouse,
rabbit, and human tissues) gives a glimpse into how difficult it
may be to define the mechanism of indirect PBM in molecular
terms, without knowing the underlying cellular- and organ-
level mechanisms involved. Further, the multipotency may
limit—certainly complicate—the use of stem cells in therapy.
The expression by Myo/Nog cells of MyoD, for example,
imparts the capacity to differentiate into muscle.69,71 Myofi-
broblast contractions can be beneficial for wound closure in
skin, wherein Myo/Nog cells reside in a niche associated with
hair follicles, expand in number in response to epidermal abra-
sion, and populate the exposed dermis within 24 hours.68 Myo/
Nog cells also develop, however, into contractile myofibro-
blasts in the ocular lens, in response to wounding in vitro or
after cataract surgery in vivo,68,70,72,73 and there the contrac-
tions produce wrinkles in the surrounding capsule that may
impair vision postoperatively.69,70 A similar contractile phe-
nomenon may occur in the retina wherein chronic stress leads
to the formation of membranes containing myofibroblasts that
contract and cause retinal detachment.74,75 Given their propen-
sity to form muscle, any decision to implant or deplete Myo/
Nog cells for therapeutic purposes will be dependent on knowl-
edge of the properties of the target tissue.
But that is looking too far ahead. In the meantime, we note
that the resilience response induced by PBM will have to be
understood at several levels. Genome-wide analyses and anal-
yses of specific molecular pathways will play a role, but the
contribution of cell classes—like Myo/Nog cells—and
responses of the whole animal will have to be analyzed, if the
response of mammals to low-level stress is to be understood
and deployed in therapy.
Innovations. One measure of the success of a technology is the
investment made in the technology itself. The technology of
“PBM” has extended from Finsen’s red filters to wavelength-
specific lasers,11 to wavelength-specific LEDs,17 to delivery
into the brain by optical fibres37 and intranasal probes,38 to
most recently, the development of infrared-emitting cloth pow-
ered by body movement (reviewed by Tsai and Hamblin41).
Not all these techniques may prove clinically useful, but there
is appeal in the idea, already being tested,41 of speeding the
healing of a skin wound or damaged tendon with a bandage
that, powered by limb or body movement, emits an appropriate
dose of infrared. This field, like all those reviewed below, is
expanding rapidly, in ways difficult to anticipate.
One future innovation can be inferred from our still incom-
plete understanding of the indirect or remote effects of PBM,
just discussed. This is the possibility that a regular dose of
PBM, directed and calibrated by data yet to be complete, might
be good for body-wide health, in the way we already believe
that exercise and a healthy diet and intermittent hunger (all
discussed below) can be. It seems an intriguing, promising
idea, but an idea for some future review.
Ultraviolet Light (UV, 290-400nm)
The evidence that UV light increases the resilience of skin begins
with Finsen’s9 evidence, alreadymentioned, that “themost refran-
gible rays” of visible light (blue andviolet but likely includingUV)
promote skin healing in lupus vulgaris, an aggressive form of
tuberculosis affecting the skin. The mechanism of this healing has
not been identified; after Finsen’s 1903 report, tuberculosis was
increasingly prevented by vaccination or cured by drugs, and Fin-
sen’s evidence appears not to have been further analyzed.
Amore familiar example is seen in the several effects of UVB
light (290-320nm) on normal skin. At high intensities, UVB is
toxic to the skin, downregulating immune mechanisms in the
skin, inducing inflammation, DNAdamage, andmalignant muta-
tions. At low daily doses, UVB conditions the skin, making it
resistant to sunburn,76 and induces also the synthesis of vitamin
D,76-79 which is essential for calcium absorption and bone struc-
ture and inhibits the onset of several cancers. It has not yet been
established whether UV at low daily doses, such as those appro-
priate to induce vitamin D synthesis and adaptive responses such
as mild tanning, is protective against tumors of the skin itself.
White Light (400-700 nm)
The retina. Under ideal conditions, rod photoreceptors can sig-
nal the capture of a single photon.80 This sensitivity is achieved
by the amplification process of the phototransduction cascade,
whereby the absorption of photons by rhodopsin in a rod outer
segment leads to hyperpolarization of its axon terminal and a
reduction in the release of glutamate from the terminal—the
beginning of vision.
This sensitivity comes at a price, demonstrated 25 years ago
by Penn and Anderson.81 They raised rats in darkness and
showed that light-naive photoreceptors grow long outer seg-
ments with beautifully organized membranes, while the outer
segments of photoreceptors from animals raised in more
Stone et al 5
normal conditions (12 hours in darkness, 12 hours in mesopic
conditions) were shorter and their membranes were damaged.
But when the animals were exposed to bright daylight, light-
naive photoreceptors were destroyed catastrophically, while
photoreceptors with some light experience and damaged outer
segments survived daylight robustly. Their work and subse-
quent studies (eg, the study by Liu et al82) showed that rat
photoreceptors are conditioned by normal light experience to
be resilient when exposed to potentially damaging levels of
light. Again, low levels of stress—in this case of wavelengths
found in daylight—induce resilience.
Other tissues. Although there is a long tradition of healing of
body tissue by sunlight,83 few studies of broad-spectrum (white)
light have appeared in the peer-reviewed literature. Several
groups have, however, tested wavelengths within the white spec-
trum. Adamskaya and colleagues84 reported that blue light (470
nm) accelerates wound healing in a rat model, improving blood
flow by inducing the release of NO; Fushimi and colleagues85
reported that red (638 nm) and green (518 nm) light accelerate
wound healing and Yuan and colleagues86 observed that blue
light (424 nm) protects liver and kidney tissue from ischemia–
reperfusion damage. This evidence is limited but does suggest
that broad-spectrum daylight, at appropriate low doses, induces
tissue resilience. As a generalization, there seems to be an
evolved mechanism by which skin uses the stress of everyday
light to upregulate a wound healing response.
Ionizing Radiation: The Debate Over Radiation Hormesis
Interest in the biological effects of low-dose ionizing radiation
has been stimulated by (at least) 2 imperatives. One was to
learn as much as possible from the mass exposure of civilians
to such radiation, in the nuclear bombing of 2 Japanese cities at
the end of World War II. The other has been and remains to
understand the risks to people exposed to low levels of radia-
tion—patients who need radiotherapy, their radiologists, min-
ers of radioactive materials, and engineers creating specialized
forms of radiating materials.
The damaging effects of high-dose radiation are clear
enough. One simplifying assumption, relied on for several
decades after World War II, was that rates of tissue dam-
age—particularly of DNA damage and its sequelae—at low
doses could be extrapolated linearly from high-dose effects,
for example, an increase or decrease in cancer risk of 4.5%
to 7.1% per Sievert.87 This was also a safe assumption, one
that responded to the fears of those subject to low-dose radia-
tion. By the 1980s, however, the assumption was under chal-
lenge. In one early challenge,88 it was noted that, at the time of
publication (1983), there were *1000 papers in the literature
giving evidence that low-dose ionizing radiation (typically
1-50 cGy89) is not weakly toxic, as expected from the extra-
polation hypothesis. Rather, it was surprisingly and distinctly
beneficial to tissues. Hickey and colleagues88 argued that “the
ignoring of the hormesis phenomenon seems to constitute a
very serious error in modern biomedical science and in
preventive medicine.” Their papers introduced the term radia-
tion hormesis into the literature.
In 1991, Macklis and Beresford89 reviewed what was already
an almost bewildering array of evidence: that cells in vitro con-
ditioned with low-level ionizing radiation (their acronym was
LLIR) are resistant to subsequent radiation at higher doses, sug-
gesting a stress-inducible DNA repair mechanism; that LLIR
induces DNA synthesis and increases antioxidant (glutathione)
expression, slowing cell metabolism and increasing protection
from reactive oxygen species; and that LLIR is immunostimu-
latory, even relatively high doses of radiation that induce a tran-
sient leukopenia and suppression of antibody production also
inducing a longer period of higher-than-normal leukocyte and
antibody production, associated with a resistance to transplanted
tumors. They reviewed ideas that lack of exposure to LLIR may
be “subtly detrimental” to cells, the way wind deprivation causes
the early collapse of trees (below); that LLIR stimulates the
growth and fecundity of organisms in general; and that in plants,
LLIR induces a modest but measurable increase in linear growth,
branching, and flowering. These authors were clearly intrigued
by the diversity and the cumulative weight of the evidence then
available for review, but they were also cautious, remarking that
they found many individual studies “unconvincing.”
Despite this skepticism, experimental work continued (Figure
1), and reviewing the data available 2 years later, Loken and Fei-
nendegen90 were bolder in their conclusions. The idea of radiation
hormesis could not, they argued, be ignored. A further year on,
Smith91 concluded that the beneficial effects of low-dose ionizing
radiation had been convincingly demonstrated experimentally, but
were cautious about its implications for humans, arguing that there
was “no overwhelming evidence” that conditioningwith low-dose
irradiation reduces the occurrence of cancers.
By 1998, an investigator from the US Nuclear Regulatory
Commission92 specifically recommended recognition of radia-
tion hormesis as a better basis (than the linear extrapolation
hypothesis) for minimizing the environmental risk of radiation.
Figure 1. Publications per year relating to radiation hormesis,
assessed by the occurrence of the term in their title or abstract; from
PubMed.
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And a year later, Luckey93 noted increasing evidence that natu-
rally occurring low-level radiation reduces cancer rates in
human populations and proposed low-level ionizing therapy
for the prevention of cancer, the opposite of the effect assumed
from the linear extrapolation hypothesis.
The debate remains active and productive of new ideas, and of
response to them, for the increasing confidence of some investiga-
tors evokes a reaction from others. Mossman94 wrote in 2001 of
“deconstructing” radiation hormesis. In 2009, Jolly and Myer95
reviewed the tensionbetweenempirical findings, official policy, and
boldly speculative ideas of the implications of radiation horm-
esis,96 and tentative views have persisted.97,98 Very recently,
impatience with the long debate eventually surfaced, with
reviewers declaring the linear no-threshold hypothesis to be
“dead at age 89.”99
We would add only 2 comments. One is that modern ani-
mals have evolved in an environment that has always contained
LLIR; there should be no surprise, at least in hindsight, if
today’s genomes coded for the detection of the stress caused
by such radiation and for the upregulation of a protective
response. And second, the demonstration of low-level effects
can be striking. Otani and colleagues,100 for example, tested
whether low-dose g-radiation makes photoreceptors in the rat
retina resistant to potentially damaging levels of white light.
The result was affirmative, reinforcing earlier evidence that
low-level radiation is “good for us.” If it can slow neurodegen-
erations (itself a remarkable claim), who knows what else?
More research seems certain in this important, ideas-rich area.
Food
Our nutritional requirements are usually understood to comprise
carbohydrates, protein and fats, plus the vitamins and a range of
minerals in small amounts. In recent decades, understanding has
grown that something else in the plants we eat is good for us,
reducing morbidity and delaying mortality in people with no
nutritional deficiency. The idea has a background in at least 2
lines of observations. One is that a diet rich in vegetables, com-
monly called the “Mediterranean” diet, is associated with lower
rates of cardiovascular disease and malignancies101,102; for a
meta-review see Bloomfield et al.103 A vegetable-rich diet is
thought of as good for our health, in the same vague way that
we have long thought of moderate exercise and sunlight as being
“healthful” (note 1). What is it with vegetables that can prevent
diseases as severe as atherosclerosis and cancer and the neurode-
generations? The second line of observations comes from the
extensive use of plants in traditional medicines, particularly the
Islamic, Indian, and Chinese traditions, which seem, despite their
lack of controlled trials, to deliver much.
The Resilience Induced by Certain Foods
In the past 30 years, the biomedical literature has seen the
emergence of lines of studies, each focusing on the therapeutic
potential of a chemical found in plants. Typically, the plant has
had a long history in traditional medical practice, and the peer-
reviewed literature on the compound began in the 1980s or
1990s and has grown exponentially since (Figures 1–4).
These chemicals are known as phytochemicals or, less cau-
tiously, as phytotoxins—“phyto” because they have evolved in
plants, “toxins” because they are demonstrably toxic to animals
at higher doses. Botanists were initially unsure of their roles
and gave them a noncommittal name, “secondary metabolites.”
Figure 2. Perhaps stimulated by the relatively high levels of resvera-
trol in plants used in Chinese traditional medicine,104-106 and in red
wine, studies of resveratrol appeared in the peer-reviewed literature
in the late 1980s and interest has grown rapidly since. At the time of
writing, the total of papers in the PubMed database in which
“resveratrol” appeared in the title or abstract was 8800. Of these,
in 23% the title or abstract included “cancer” and in 1.7% included
“neuroprotection.”
Figure 3. The time course of peer-reviewed studies of lycopene also
begins in*1990 and growing rapidly since. Approximately 24% of that
literature concerns cancer, and a very small minority (0.1%, we found
just 5 studies, not discernible on this graph) concerns neuroprotec-
tion. Overall, the number of studies on lycopene is about one-third of
the number available for resveratrol.
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In recent decades, the roles of plant secondary metabolites have
been increasingly elucidated and (reviewed in the study by Sun
et al107) include the discouragement of other plants competing
for resources and protection from attack by those other plants
(in a process botanists call allelopathy107) and discouragement
of animal predation.108 Four examples are considered below—
resveratrol (evolved in red grapes and Japanese knotweed),
curcumin (in turmeric), lycopene (in tomatoes and waterme-
lon), and crocin (in saffron). Others less studied include allicin
(garlic) and the catechins (green tea).109 Chemically, they are
small molecules, many strongly antioxidant. Many are caro-
tenes (crocin, lycopene, resveratrol), phenols (curcumin, cate-
chins), or organosulfurs (allicin).
Mammals coevolved with plants and, for some plants, we
have not evolved sufficient defense against or tolerance of their
toxins. Ingesting small amounts of such plants makes us thor-
oughly ill; for us, such plants are “poisonous.” But the plants
we regard as edible, and rely on for nutrition, also produce
toxins and current evidence indicates that mammals (most
work has been done in rodents and humans) have evolved an
identifiable response to these toxins. In this response, low
doses of the toxins upregulate mechanisms of tissue resilience.
At high doses, all the phytotoxins are tissue destructive
(Table 1), but the high-dose-toxic part of the response attracts
little investigation. It is the low-dose-resilience response that is
strikingly counterintuitive, therapeutically promising, and
increasingly investigated.
Resveratrol
Resveratrol is produced by many plants, including a plant
known in Chinese medicine as Huzhang (in English as
“Japanese knotweed”), long used for a range of cardiovascular,
digestive, and metabolic complaints, and more familiar to
Western culture, by red grapes, in which it concentrates in the
skin and finds its way into red wine. Its presence in wine has
been discussed as a happy explanation of the low rate of cor-
onary heart disease among the French (the French paradox).116
In our reading of this literature, we were struck by the vari-
ety of morbidities—including cancer and cardiovascular dis-
ease—against which resveratrol had been tested; by the
apparently uniformly positive effects of low-dose resveratrol
in a wide range of nonhuman models; and by the difficulty of
translating these effects to clinical trials. This difficulty is not
absolute, but it seems likely that the delivery of resveratrol to
human tissues will need to be improved, before the remarkable
therapeutic potential suggested by now thousands of experi-
mental studies of resveratrol is realized clinically.
The literature on the mechanisms of resveratrol’s action is
diverse and difficult to summarize. One recent review summar-
ized it this way117:
Amidst much confusion, it has become clear that resveratrol
potentially has several direct targets in the cell. Although the
original discovery was as a cyclooxygenase inhibitor, it has
subsequently been identified as an activator of Sirt1 . . . ; an
inhibitor of cAMP phosphodiesterases . . . ; an inhibitor of the
F1-ATPase . . . ; an inhibitor of the estrogen receptor . . . , and a
modulator of numerous other targets.
The experimental evidence that resveratrol can induce tissue
resilience seems strong, in animal models and in studies in
vitro. Resveratrol has been reported—these are just a few
examples—to attenuate apoptosis induced in cerebrovascular
endothelial cells by oxidized low-density lipoprotein (LDL)
fats118; to slow diabetic retinopathy by downregulating oxida-
tive stress and inflammation119; to inhibit the invasiveness and
Figure 4. Interest in curcumin has been as high as or higher than in
resveratrol. Again a large minority of studies (30%) address cancer and
a small minority (4%) address neuroprotection.
Table 1. Sample Reports of the Toxicity of Selected Phytochemicals.a
Lethal Dose 50%
(LD50) Toxic Dose Low (TDLO)
Resveratrol No published data
found
<2 g/d110 (human)
Lycopene >3 g/kg (mouse)111 1.43 g/kg (human; http://www.ce
nterchem.com/Products/Do
wnloadFile.aspx? FileID¼7345)
Curcumin 5 g/kg112 (rat); 2
g/kg113,114
(mouse)
12.6 g/kg (https://www.spe
ctrumchemical.com/MSDS/TCI-
C2302.pdf)
Saffron >0.6 g/kg
(rodents)115
No published data found
aThe phytochemicals with protective properties are all toxic at some high dose,
which varies with how it is prepared, how delivered, and how assessed.
Typically, the toxicity of something for whole animals is assessed as the
LD50 (the dose lethal to half the cohort tested); for humans as the TDLO
(the lowest dose at which toxicity is detectable); and for cells in vitro as the
IC50 (half the concentration that fully “inhibits”/kills the cells). In animals,
TDLO measures have been devised to test a range of responses, including
skin irritation, corneal irritation, reproductive success, and DNA damage
(genotoxicity). As a generality, the tissue-protective properties of the phyto-
chemicals discussed below (and of many others) are apparent at doses that are
not toxic by any of these measures.
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migration of pancreatic cancer cells120; to inhibit androgen-
driven proliferation of prostate cancer cells121; to inhibit the
viability and induce the death of colon cancer cells122; to
induce differentiation and apoptosis in anaplastic lymphoma
cells123; to maintain mitochondrial integrity; to downregulate
insulin-like growth factor 1, activate SIRT1, increase the life
span of yeast and mammals (reviewed in the study by Morris
et al and Sun et al124,125); and to protect central nervous tissue
in models of brain damage and degeneration.125 Work is begin-
ning on the ability of resveratrol exposure to pregnant rats to
improve the health of their offspring, for example, to reduce the
susceptibility of offspring to toxin-induced carcinogenesis.126
And the protection provided by resveratrol against cancer is
being traced, for example, to its ability at low concentrations to
stabilize spindle assemblies during mitotic division of normally
mitotic cells.127 The horizons of study of resveratrol, indeed of
all the resilience-inducing interventions considered here, con-
tinue to broaden.
Many of these studies go to mechanisms, which are also
diverse. Bitterman and Chung117 (quoted above) reviewed
“controversies” concerning these mechanisms. The debates
they review are real, but these debates are not about the ability
of resveratrol to influence known molecular pathways. Rather,
they are about the detail of that influence, whether, for exam-
ple, the regulation of sirtuins can or cannot be the basis of all of
resveratrol’s many known actions. The authors conclude that
resveratrol is pleotropic, polypharmacological and that it reg-
ulates many target pathways. This is a recurring feature of the
accounts of other resilience-inducing interventions.
Lycopene (Tomatoes and Watermelon)
Lycopene is a carotene found in red-colored fruits and vegeta-
bles, and gives their red color to tomatoes and watermelon.
Many recent reviews128-134 are available of the effect of lyco-
pene on a range of diseases.
Cancer. Prominent in these reviews and primary data studies is a
line of evidence that lycopene found in tomatoes and tomato
sauce reduces the incidence or limits the spread of prostate
cancer, and perhaps of other cancers. Studies presented evi-
dence, for example, that the consumption of tomatoes is inver-
sely related to the incidence of prostate cancer,128 that dietary
tomatoes or lycopene increase serum lycopene,135 and that, in
vitro, lycopene promotes apoptosis and inhibits proliferation
and metastasis in cell line models of prostate136 and other134
cancers; the analysis of mechanisms has begun.
The idea that phytochemicals can be “anticancer” is not
new. One, called paclitaxel, has been a first-line drug for the
treatment of several cancers137 since it emerged from a 1960s
screen, supported by the US National Institute for Cancer, of
anticancer substances. Paclitaxel at sufficient dose (in practice
limited by the ability of the patient to tolerate it) stops the
formation of microtubules in actively dividing cells, whether
malignant or normal, resembling other chemotherapy drugs,
with similarly harsh side effects. The action described here for
lycopene and passim for other phytochemicals is very different;
it is achieved at doses that are well below toxicity and induces a
positive “cellular stress response” in normal tissues, while sup-
pressing metastasis and proliferation in malignant cells.
By 2004, the evidence that lycopene at nontoxic doses was
effective against prostate cancer had gained sufficient momen-
tum that the US Food and Drug Administration (FDA) received
2 petitions, leading it to take a position on the matter. The
FDA’s response was published in 2007.138 It was discouraging;
having assessed the quality and outcomes of many studies, the
authors of the response found “no credible evidence to support
an association between lycopene intake and a reduced risk of
prostate, lung, colorectal, gastric breast, ovarian, endometrial,
or pancreatic cancer.” Similarly, they found no credible evi-
dence of an association between tomato consumption and a
reduced risk of lung, colorectal, breast, cervical, or endometrial
cancer. But they did report “very limited evidence” of an asso-
ciation between tomato consumption and reduced risk of pros-
tate, ovarian, gastric, and pancreatic cancers.
It was an important statement from an authoritative group,
and a 2011 review of randomized control trials of the value of
lycopene in prostate cancer139 was similarly discouraging. Ten
years on from the FDA report, neither lycopene nor any other
phytochemical has become part of mainstream management of
the risk or treatment of prostate cancer.
Nevertheless, interest in the association persists in many
forms. Giovannucci,140 in a rapid single author response to the
FDA’s 2007 statement about lycopene, argued that the evalua-
tion of prostate cancer outcomes in humans had been compli-
cated by the increasing reliance on the periodic–Schiff acid test
over the years reviewed by Kavanaugh and colleagues, effec-
tively creating noise in which the signal of prostate response
was lost. The same group subsequently141,142 developed evi-
dence that lycopene exerts its effect on a subtype of prostate
cancer characterized by a specific protease, partially explaining
prior mixed findings. At the other end of a range of studies and
reviews, a group of 180 scientists/authors143 met in 2013 and,
after working in 12 teams over 2 years, published in 2015 a
“broad-spectrum” review of dozens of chemical (predomi-
nantly phytochemical) interventions in a range of cancers, tar-
geting a large range of mechanisms. Their summaries, which
include but go far beyond lycopene, indicate that, for a list of
59 interventions (their Table 2), *1% of outcomes were
“contrary,” appearing to be pro-cancer; *3% outcomes were
“controversial,” with mixed results; 62% outcomes were
“complementary” or anticancer; and 34% were “unknown,”
with no clear result. Within their data, studies of lycopene
followed this pattern (0, 0, 8, 3 studies in the 4 categories),
as did the studies of resveratrol (0, 2, 9, 0 studies in the 4
categories) and curcumin (0, 0, 11, 0 studies in the 4
categories).
In summary, the debate over the effectiveness of lycopene
for the prevention of prostate and other cancers, or for treat-
ment, usually as an adjunct to medically accepted interven-
tions, has widened—despite the 2007 FDA statement—to
include a large range of phytochemicals and a large range of
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underlying mechanisms. It seems to be a progressive debate,
dealing with issues of study organization, genetic variation
within cancer types, and the complications of diagnosis and
of the assessment of disease progress or regression. It is also
a lively debate, made urgent by the aching need for effective
treatment of still intractable cancers.
Cardiovascular health. The evidence that lycopene consumption
is beneficial to cardiovascular health shares features of the
lycopene and cancer data just reviewed. At the laboratory level,
for example, Armoza and colleagues164 reported that the car-
otenoids lycopene and lutein attenuate the adhesion of inflam-
matory leukocytes to endothelium, identifying attenuation of
NF-kB and several other molecular pathways as important in
the action; Fletcher and colleagues165 reported that lycopene
supplementation reduces an adhesion phenotype in peritoneal
cells; in a study of human and animal endothelial cells in vitro,
Lee and colleagues166 concluded that lycopene enhances bar-
rier integrity and inhibits monocyte adhesion and migration to
(inflammatory) human vascular endothelial cells by blocking
activation of pro-inflammatory cytokines and expression of
cell adhesion molecules and high-mobility group box 1 recep-
tors; Zhu and colleagues167 reported that in diabetic rats, lyco-
pene increases LDL levels and inducible nitric oxide synthase
(iNOS) activity and reduces superoxide dismutase (SOD)
activity, NO levels, and constitutive NOS activity, reducing
endothelial cell dysfunction; and Bae and Bae168 reported, in
an in vitro study of human endothelial cells, that lycopene
enhances barrier integrity and inhibits leucocyte adhesion and
migration to endothelial cells by blocking the activation of
NF-kB, CD14, and TLR4 expression and production of tumor
necrosis factor a. This sample of a wide literature suggests that
there is ample proof-of-principle evidence that lycopene should
enhance the health of blood vessels in humans.
In human studies, Rissanen and colleagues169 tested the
hypothesis that low serum levels of lycopene are associated
with an increased incidence of acute coronary events and stroke
in middle-aged men. They reported that men in the lowest
quartile of serum lycopene, followed over 6 years, had a
3-fold greater incidence of coronary heart disease or stroke;
this confirmed an earlier report.170 Burton-Freeman and
Sesson171 and Friedman172 reviewed evidence that dietary
supplementation with lycopene or tomatoes is associated with
a lowering of blood pressure in both normotensive and hyper-
tensive individuals, with improvements in lipid metabolism
(eg, raised high-density lipoprotein) and improvements in
endothelial cell function (lower intercellular adhesion) and
reductions in inflammatory responses of the endothelium;
Gajendragadkar and colleagues173 reported, from a randomized
controlled trial, that lycopene supplementation improves
endothelial cell function, assessed by a range of tests, in
patients with cardiovascular disease, although not in healthy
volunteers; Wolak and Paran174 reviewed the literature on the
effect of lycopene and other carotenoids on cardiovascular
parameters, concluding that the effects include a decreased
incidence of diabetes, lower LDL levels, improved blood pres-
sure control, and a reduction in carotid intima–media thickness,
a marker for atherosclerosis; Ried and Fakler175 undertook a
meta-analysis of the protective effect of lycopene on serum
cholesterol and blood pressure, concluding that the evidence
is consistent that lycopene at doses of 25 mg/d lowers total
serum cholesterol and LDL levels, as well as blood pressure.
Again, this is only a sample of a wide literature, but it supports
the underlying hypothesis that lycopene, a highly antioxidant
carotenoid, activates a range of pathways that enhance the
resilience of vascular tissue.
Neuroprotection. A small number of studies of the neuroprotec-
tive action of lycopene have appeared. In animal studies, for
example, Lei and colleagues176 reported that pretreatment of
rats reduced cell death and functional loss in a model of stroke,
the effect involving the NF erythroid 2/heme-oxygenase path-
way; Yin and colleagues177 reported that cognitive impairment
induced in rats by consumption of fructose is ameliorated by
lycopene administration; Prakash and Kumar178 and Yi and
colleagues179 reported that lycopene reduces mitochondrial
dysfunction in toxin-induced models of dementia and
Table 2. Recent Reviews of Phenotypes of Resilience.a
Phenotype Recent Reviews
Acceleration of wound healing
Skin Kuffler144
Tooth sockets Khan and Arany,145 Aoki et al146
Conditioning of undamaged
tissue
Brain, retina, heart Agrawal et al147
Slowing/stopping tissue
degeneration
CNS chronic: dementia,
Parkinson, AMD
de la Torre,148 Saez de Asteasu
et al,149 Broadhead et al150
CNS acute: stroke, TBI Hamblin151
Skin Barolet et al14
Muscle Ziaaldini et al152
Reduction of genotoxicity Koul and Abraham153
Reduction of inflammation,
pain
Hamblin154
Supernormal function
Muscle Ferraresi et al155
Retina Brandli and Stone156
Accelerated recovery from
muscle fatigue
Borsa et al,157 Pinto et al,158 Toma
et al159
Suppression of cancer Block et al143
The preservation/restorability
of resilience in old age
Calabrese160
Delay of mortality (longevity) Huffman,161 Lopez-Luch and
Navas,162 Everitt and Le
Couteur163
Abbreviations: AMD, age-related macular degeneration; CNS, central nervous
system; TBI, traumatic brain injury.
aThere is some specificity to the relationship between stress and response: the
effects of light on the stability of the retina have already been noted. But that
specificity is limited; most tissues respond to most stresses, which is a distin-
guishing feature from acquired immunity. Literature references are recent, but
very partial.
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parkinsonism. In human studies, Karppi and colleagues180
reported that high serum levels of lycopene are associated with
a decreased risk of ischemic stroke, which may of course result
from the vessel-protective action of lycopene described above.
On the other hand, in studies of diet and the risk of amyotrophic
lateral sclerosis181 and multiple sclerosis,182 serum lycopene
showed no clear association with risk. Further experimentation
and observation are required, but it is possible that lycopene
will prove to be as protective to the central nervous system
(CNS) as resveratrol, curcumin, and saffron.
More generally, the study of the tissue-protective effects of
phytochemicals is still evolving. Most studies focus under-
standably on one phytochemical, such as lycopene, or on one
measure of tissue pathology, whether anticancer effects, or
vascular integrity, or neuroprotection. We hypothesize that
resilience effects of phytochemicals will prove to be broad
spectrum, not specific to particular pathologies.
Curcumin (Turmeric)
Curcumin is a phenol, found in the plant turmeric. It has been
used for centuries, particularly in Indian traditional medi-
cine,183 as a spice and food coloring and as a herbal supplement
with “health” properties.
At high doses, curcumin is toxic, with an LD50 in rodents of
2 g/kg (Table 1). The peer-reviewed literature is rich with
evidence that, at low doses, curcumin is tissue protective. Many
reviews are available (as for resveratrol and lycopene) of cur-
cumin’s protective effects in a range of diseases, including
several forms of cancer,134,184-188 in dementia183,189-200 and
parkinsonism,201,202 in mitigating the inflammatory component
of aging,203,204 and in cardiovascular disease.109,205-207 These
reviews summarize hundreds of laboratory and clinical studies.
Cancer. The peer-reviewed literature (*3000 studies) on the
anticancer effects of curcumin has moved past establishing the
reality of the effects to analyses of their mechanisms and to
studies of how curcumin can be best configured and delivered.
Curcumin has, for example, been reported to enhance the effect
of cisplatin in suppressing the growth of squamous cancer cells
in vitro and the suppression of xenograft tumors in vivo,
mediated by the inhibition of cellular IKKb208; to mimic the
antiproliferation and cell death actions of valproic acid, by the
same mechanisms (increasing Sp1 binding and the acetylation
of the histones H3 and H4 in the promoter region of bax)209; to
be cytotoxic to glioma cells in vitro, by regulating cell death
pathways210; not to act synergistically with histone deacetylase
inhibitors in their actions on cancer cell lines in vitro211; to
induce apoptosis in human hepatocarcinoma cells in vitro, by
disrupting the membrane potential of mitochondria and dis-
turbing the intracellular concentration of calcium ions212; to
reduce radiation-induced damage of the parotid glands in a rat
model of the radiation of human head and neck cancers213; and
to enhance the effect of ultrasound in the destruction of naso-
pharyngeal carcinoma cells in vitro.214
These consistently positive results from cell line and animal
models of cancer have led to many clinical trials of curcumin
related to cancer. Their results are more mixed, several authors
suggesting that in humans the bioavailability of curcumin may
be limited.215-217 Farzaei and colleagues218 and Maru and col-
leagues185 concluded that, despite extensive experimental evi-
dence of the effectiveness of phytochemicals such as curcumin,
evidence was “still lacking” from large-scale clinical trials.
Responding to the problem of bioavailability, studies have
been launched of the absorption, bioavailability, and metabo-
lism of curcumin, delivered in various ways—unformulated
and reformulated (with nanoparticles, liposomes, chaperone
molecules) in attempts to improve bioavailability. By 2014,
Pavan and colleagues186 were able to list 46 studies of refor-
mulations of curcumin (their Table 1) designed to improve its
bioavailability. Their summary is cautious:
Since ancient times, curcumin has been used in Asian countries
against human ailments. . . .Multiple studies over the past
decade have indicated the safety and efficacy of this polyphenol
and have provided a solid basis for evaluating its efficacy in
human clinical trials. Despite its efficacy and safety, limited
curcumin bioavailability continues to be highlighted as a major
concern. However in attempts to improve the bioavailability of
curcumin, several strategies have been explored such as mod-
ulation of route and medium of curcumin administration, block-
ing of metabolic pathways by concomitant administration with
other agents, and conjugation and structural modifications of
curcumin . . . . In spite of these improvements, curcumin bioa-
vailability, enhancement and efficacy have not gained signifi-
cant attention in human studies . . . . Further . . . attempts to
enhance the bioavailability, medicinal value and application
of this interesting molecule . . . are needed.
Judged empirically (from Figure 4), however, scientists in this
field are reporting on curcumin—its efficacy in in vivo and in
vitro models of cancer, its safety, reformulation, and clinical
value—at a steadily increasing rate. By this criterion, at least
there is growing confidence in and excitement about the poten-
tial of this phytochemical to improve the treatment of still
deadly diseases.
Inflammation, cardiovascular health, and neuroprotection.
Although logically these are independent targets for a tissue-
protective molecule, for curcumin they have often been studied
together. Bala and colleagues,219 for example, reported that a
curcumin-enriched diet mitigated the normal age-related
increases in lipid peroxidation and lipofuscin in the rat brain
and mitigated age-related decreases in the expression of anti-
oxidant molecules and of enzymes related to ionic transport,
and Sikora and colleagues203,204 have argued that chronic
inflammation is a factor in age-related diseases, including the
cancers, atherosclerosis, and the neuropathology of dementia.
The implication is that it is the anti-inflammatory action of
curcumin that underlies its anticancer, neuroprotective, and
vascular-protective effects. Reviewers focusing on the role of
curcumin in dementia have focused correspondingly on the
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anti-inflammatory and antioxidant mechanisms induced by
curcumin,183,205 while others have stressed curcumin’s ability
to mitigate age-related changes in protein homeostasis that lead
to deposits of insoluble proteins or debris, citing Ab, tau, or
lipofuscin as examples of molecules whose deposition is both
disease related and mitigated by curcumin198,201
This difficulty in separating the anti-inflammatory from
the vascular-protective actions of curcumin (or any phyto-
toxin) presumably arises from the vascularity of the brain.
We have argued elsewhere, for example,220 that age-related
dementia (Alzheimer disease) is a small-vessel vascular
dementia, caused by the destructive effect of the aging pulse
on cerebral arterioles and capillaries. The protective effect of
curcumin against Alzheimer disease could be mediated by
the stabilization of proteins considered specific to the dis-
ease, by the enhancement of neurogenesis,198 by restoring
redox homeostasis199 in the vulnerable neurones, or by the
upregulation of antioxidant and cell survival pathways.108,206
Since these pathways are present in probably all cells, the
protective effect of curcumin on the aging brain could arise
from stabilization of its neural tissues or of its vasculature or
of both tissues.
Challenge. Finally, the value of curcumin in all these roles has
recently been subject to a robust challenge.221 Writing from
the point of view of medicinal chemists, Nelson and col-
leagues argue that curcumin is both a PAIN and an IMP—a
pan-assay interference molecule (one that interferes with
other pathways) and an invalid metabolic panacea (a mole-
cule for which wide-ranging benefits have been invalidly
claimed). Their case is argued powerfully; as Finsen might
have commented, the claims made for curcumin are “too
marvelous,” and the explanations offered attract skepticism.
Skepticism is essential to scientific method, but it is not an
end in itself, and it seems to the present writers likely that
curcumin and other phytochemicals may never escape these
negative categories of medicinal chemistry, for there may be
more going on than medicinal chemistry. Low-level toxins
may induce tissue health by a distinct mechanism, as dis-
tinct for example as immunotherapy for cancer is from che-
motherapy. Why did plants evolve these molecules? If they
are defensive toxins, then it is not surprising that they evoke
a reaction from the tissues of herbivores; it is no longer
surprising, as Murugaiyah and Mattson108 have argued, that
reaction has—to low doses—evolved to be self-protective.
The phytochemicals may never pass muster as medicinal
chemicals; they seem more likely to be stimuli to endogen-
ous tissue-protective mechanisms evolved by animals in
their struggle for survival, in some sort of long-term bal-
ance, with the plants on which we/they rely for food. It is
that interaction that we, and Calabrese and Mattson and
many others before us, seek to understand, seek at least to
develop a conceptual framework within which this under-
standing can be approached.
Crocin (Saffron)
Saffron is the most legendary of the plants whose chemicals
have been shown to induce tissue-protective responses in our
tissues. Histories of saffron222,223 tell of its antiquity in agri-
culture, of the spread of its cultivation, of merchants put to
death for adulterating it, of towns named after it, of recipes and
medicinal preparations developed with it, and of the use of
saffron as a pigment for religious robing. It was so coveted
in medieval Europe to ward off the plague that it became prized
booty for Mediterranean pirates and in a struggle (the “Saffron
War” of 1374) between the aristocracy of the Swiss city of
Basle and its merchants, who had grown powerful trading saf-
fron after the Black Death pandemic in the middle of the 14th
century.222
Saffron consists of the stigmata of the flower of Crocus
sativus, a small flowering plant of the family Iridaceae,
3 stigmata in each flower, each stigma (or “thread”) weighing
*2.5 mg. The threads must be harvested by hand (from*130
000 flowers to yield 1 kg), this labor making it the most expen-
sive of spices. Their color is deep red, their aroma distinctive
and rich. Major bioactive molecules, including safranal, dis-
solve readily into water, yielding an infusion readily ingested.
The plant does not survive in the wild and has survived only
because of the regard in which humans hold it and our willing-
ness to hand-cultivate it. Although it is the stigmata (reproduc-
tive organs) of the flower that are the spice, the plant is a
triploid mutant and cannot reproduce sexually. So the prized
stigmata have lost their evolved function, and reproduction is
by cloning of corms.
Saffron is used in many strands of traditional medicine—
Islamic,224 Indian,225 and central and southern Eur-
opean225,226—and it was not a pure guess when scientists began
to test its tissue-protective properties, now established in 2 main
areas, cancer and neuroprotection. The growth of these scientific
Figure 5. Interest in saffron or its major bioactive component crocin
has been less than in resveratrol, lycopene, or curcumin, but it shows
the same time course, beginning in the 1980s and growing rapidly
since. Again, a significant minority (9%) of the studies concern cancer
and a small minority (0.9%) concern neuroprotection, but make per-
haps the most audacious claims—that saffron can slow otherwise
intractable degeneration of central nervous tissue.
12 Dose-Response: An International Journal
investigations has followed that of resveratrol, curcumin, and
lycopene (Figure 5), but studies of saffron are fewer in number
(about 2000 at time of writing, as against 10 000 for resveratrol).
For several of the authors of this review, saffron was our intro-
duction to the phytotoxins, and it was a relief when it emerged
that the ability to achieve outcomes as remarkable as to slow
neurodegenerations is not unique to this long-prized spice. Saf-
fron is effective, but so is resveratrol, harvested from a notorious
weed (above). The glamor of a plant is one thing; its value as a
source of tissue-protective chemicals is another.
In common with all phytochemicals, saffron at high doses
causes illness; for humans, ingesting 5 g (*2000 threads)
induces intestinal bleeding, and an LD50 has been reported in
rats (Table 1). At low doses, remarkable tissue-protective prop-
erties have been described for saffron in animal models, includ-
ing protection of retinal photoreceptors in a LD model of
macular degeneration,227,228 involving widespread changes in
the expression of genes and ncRNAs43; the mitigation of DNA
damage (so prevention of cancer) by the forming of specific
complexes with DNA229-231; and the mitigation of toxin-
induced pathology in the brain of a mouse model of
parkinsonism.232
In the treatment of cancer, many saffron studies are avail-
able from cell or animal models. Among the earliest was the
work of Nair and colleagues225,233 who reported that orally
administered saffron extended the life of mice implanted with
several forms of tumor and that in vitro a saffron extract was
cytotoxic to several lines of tumor cells. The effect seemed to
be mediated by disruption of DNA synthesis and to be remark-
ably specific to malignant cells, leaving “untransformed,
normal” cells unaffected. A decade later, Abdullaev and Espi-
nosa-Aguirre234 reviewed the growing literature, noting that
saffron, or its major and most tested component crocin, is very
low in toxicity but decreases lipoprotein oxidation in humans
vulnerable to coronary artery disease; counters ethanol-induced
loss of cognition in mice; has antihypertensive, antinocicep-
tive, and anticonvulsant actions; protects nuclear DNA from
genotoxic agents; and, as Nair and colleagues had reported,
slows tumor growth in rodent models and is cytotoxic to malig-
nant cell lines in vitro. A decade and half further on, the interest
in saffron in cancer continues to grow; studies have been pub-
lished of ways of increasing the bioavailability of saffron or
crocin235-238; on newly discovered aspects of its mechanism—
such as the suppression of multidrug resistance genes239,240;
and of the value to summarizing saffron’s many therapeutic
properties as “saffronomics.”241
Still lacking are major clinical trials of saffron with patients
with cancer; only small trials have been reported.242 Anecdo-
tally, it is clear that sufferers—presumably because of the
urgency of their need—are including saffron among the phy-
tochemicals with which they supplement mainstream treat-
ment, but this use is not yet scientifically controlled; to date,
it is the afflicted supplementing their mainstream treatment
with low-toxicity phytochemicals with anticancer reputations,
in the time of their need.
In disease or degenerations of the CNS, by contrast, clinical
trials of saffron are available—small trials, some double-blind,
have reported the stabilization of age-related macular degen-
eration (AMD) in humans,243 improvement in cognitive per-
formance244-246 in dementia (Alzheimer disease), and relief of
depression.246-249 Falsini and colleagues’ work on dietary saf-
fron in early “dry” AMD is an example of what has been
achieved in small-scale trials. Building on the pioneering
experimental work of Maccarone et al in a rodent model,227
they showed in a cross-over, double-blind format that 20 mg/d
saffron improved the macular ERG and visual acuity in 23 of
25 patients243; then that the improvement is maintained (if
saffron is maintained in the diet) for over 12 months250; and
that the protective effect of saffron is independent of the genes
which regulate susceptibility to AMD.251
These are remarkable findings in neuroprotection, on a par
with those reported for resveratrol, curcumin, and lycopene.
Progress with all these phytochemicals is incomplete and vul-
nerable to the skepticism on which Finsen remarked, that it all
seems too marvelous. But the pace of scientific work on these
and other phytotoxins has reached that of a minor flood (Fig-
ures 2–5), and we may have seen only its beginning.
Summary: What’s Really “Wrong” With the
Western Diet?
The analyses above have implications that the present authors
did not expect, when we set out to write a conventional review
of what is known of certain plant chemicals, “secondary
metabolites” evolved by plants to discourage predators.
Instead—or as well—the analysis has led to an understanding
of what is wrong with the “Western” diet. This diet, typically
identified as “rich in red meat, dairy products, processed and
artificially sweetened foods, and salt, with minimal intake of
fruits, vegetables, fish, legumes, and whole grains”103 is not,
we argue, that any component of the diet—or the combina-
tion—is bad or toxic for us. On the contrary, these analyses
suggest that this diet is not toxic enough and that it lacks the
toxins of the plants prominent in the Mediterranean diet, which
comprises “olive oil, fruits and vegetables, whole grains and
cereals, legumes, fish, and nuts; low intake of red meat, dairy
products, and sweets; and moderate intake of red wine with
meals.”103 It is, we suggest, the meal-after-meal exposure to
these toxins that maintains the upregulation of tissue resilience.
Meat, sugars, and dairy products meet our needs for protein,
fats, and carbohydrates. These foods are highly nutritious but,
lacking the toxins of slightly bitter vegetables, they leave our
tissues less conditioned, less resilient.
There is an analogy in the resilience of trees. In the Bio-
sphere 2 venture, trees grown inside the sphere did not experi-
ence wind. They grew well but tended to collapse before
reaching maturity. Without wind, it turned out, trees do not
form “stress wood” at points in their branched structure where
wind normally induces the local formation of either
“compression” wood or “tensile” wood. The story of wind
stress and a tree’s response to it is more complex than this,252
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but, fundamentally, it is that trees use the stress of wind to
induce the production of tougher wood, at locations that bear
the stress. Without wind, still-young trees collapse under their
own weight (http://awesci.com/the-role-of-wind-in-a-trees-li
fe/). The analogy seems strong with still-young humans matur-
ing without daily exposure to everyday stresses—the plant tox-
ins but also daylight (above), exercise, and intermittent hunger
(below)—and “collapsing” with early morbidity and mortality.
And one implication of this suggestion is that we can hew to
the diet with which we are comfortable, but we should consider
supplementing it with the phytotoxins. The experiment has
already been done, for one phytotoxin (resveratrol253), though
interpreted slightly differently. The “goodness” of the Medi-
terranean diet is that it daily delivers low doses of a range of
poisons; who would have thought?
And one answer to this last, usually rhetorical question is
that botanists might well have thought of this reaction of ani-
mals to plants. For plant biologists have shown that modern
plants are the survivors of a long competition for resources
between plants, each evolving toxins to discourage competitor
plants and each evolving mechanisms to evade or counter the
others’ toxins. Botanists refer to this battle between plants as
allelopathy. The toxins that plants produce that discourage ani-
mal predators are an extension of the same battle, in which
plants do things that at first learning seems extraordinary. As
one example, many plants produce cyanide as a toxin, pack-
aged with a sugar (as a cyanogenic glycoside) to prevent the
cyanide killing the plant itself. The plant also produces a cya-
noglycosidase, packaged in the same leaf but separately. When
a herbivore detaches and chews the leaf, the enzyme and sub-
strate are brought together, cyanide is released, and the animal
is, well, discouraged.254
Humans can and do choose our foods, and we naturally
choose and cultivate plants that are productive, palatable, nutri-
tious, and less dramatically toxic than the cyanogenic. Still,
many of the plants we rely on as food produce toxins, and the
response of animals to their “attack” has been at least 2-fold—
to evolve metabolic pathways which can rapidly detoxify the
toxins, making the animal “tolerant” to them, and second—and
this is the message of this long section on phytochemicals—is
to evolve a general mechanism of resilience, in which the tox-
ins at low dose induce pathways of cellular resilience, the
“adaptive cellular stress response” emphasized by Mattson and
Calabrese.108,109,255 Which is a long way of saying that vege-
tables are good for us in ways we have not always understood.
The Resilience Induced by Lack of Food
(Caloric Restriction, Hunger)
It is a recurring feature of the bodies of literature brought
together in this review that they begin with surprises, then
doubts and dismissal, then reassertion of the major claims.
We could find no evidence of it, but it must surely have been
a surprise when investigators first—the work goes back at
least to the 1930s—observed that animals deprived of food
were freer of disease and lived longer. The struggle for
continuity and sufficiency of food supply had shaped animal
and human behavior and conflict. Why would restricting ani-
mals to 80% of their ad libitum diet—for humans, the 5/2 diet,
for example—possibly be good for us? That caloric restric-
tion, carefully done, produces healthful outcomes is no longer
debated; in recent reviews, for example,256 the debate has
moved on to mechanisms and doses, especially as between
chronic and intermittent restriction, and the interaction
between daytime fasting and the natural period of overnight
fasting, during sleep.257
The literature on caloric restriction—the deliberate reduc-
tion of food intake to *80% of ad libitum consumption—is
diverse and rich with ideas. Walford et al258 report a simple-to-
describe experiment in the eco-research station called Bio-
sphere 2, located in Arizona. In 1992, 8 scientists entered the
closed ecosystem, committed to 2 years of active experiments
on isolated team living, which involved a commitment to a self-
grown, nutrient-adequate diet of *2000 kcal/d. Over the 2
years, during which they maintained “excellent health and
a . . . high level of physical and mental activity,” they experi-
enced falls of body weight (*17%, leveling out after 8
months), blood pressure (*25%), blood levels of sugar
(21%), insulin (42%), and cholesterol (30%), and many other
healthful changes that had been associated with caloric restric-
tion in animals over the preceding century, and since confirmed
in humans.259 It is salutary, however, to read accounts of group
dynamics among the Biosphere 2 crew, accounts that are part
of a more general literature on isolated teams. Writing in 2015,
Nelson and colleagues260 noted that “food was a prime concern
inside Biosphere 2,” the concern arising partly from the time
and energy involved in producing it (*36% of the Biospher-
ians’ labor), partly from the pressure to maintain that labor (“if
we want it we have to grow it”) and partly because the crew
was “unused to dealing with hunger.” At the tissue level, daily
caloric restriction made the team members lean and mission
effective, but, at the psychological level, daily hunger and con-
cern about food supply seem to have made it difficult to opti-
mize group dynamics for a long and complex mission.
The stress of chronic or intermittent hunger has, we argue,
been part of the experience of mammals for so long that we
have evolved pathways that use the stress to make the body
resistant to cardiovascular and metabolic disease, reducing
morbidity and delaying mortality. It is of interest that humans
seem not to have evolved ways of extending that resilience to
our complex psychology; perhaps that element of evolution
lies ahead for Homo sapiens. If so, the justification for the
adjective sapiens will be strengthened. Following that thought
a decade after the Biospherians reported in 2002, Blagosk-
lonny261 speculated that the Slavic folklore figure Koschei the
Immortal—old, lean-as-a-skeleton, combative, magically
resilient in the face of injury directed at him because of his
relentless anger and ill-humor—may have been a caricature of
men who survive the stress of prolonged hunger, reinforced
(the author speculated) by a hunger mimetic (perhaps rapa-
mycin), into late age.
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In the intervening years and still, the scientific study of
caloric restriction has increased its pace (Figure 6), and some
researchers have concluded that caloric restriction is the most
effective intervention known for the slowing of aging.262 In
those years, the effect of caloric restriction on atherosclerosis
was confirmed by Fontana and colleagues263; Kyriazis264 sug-
gested that caloric restriction can best be understood and
deployed as a “hormetic strategy” to combat aging; and Martin
and colleagues265 reviewed the evidence that both caloric
restriction and a variant hunger strategy—that of “intermittent
fasting,” something like the 5/2 diet presently fashionable—are
effective neuroprotectants, protecting the brain from age-
related changes.
Some investigators, perhaps alarmed at the prospect of mil-
lions of people dieting to a lean, long-lasting but angry-and-
mean old age, have asked whether other interventions could
mimic caloric restriction, with a gentler outcome. Prominent
among the mimetics investigated are phytochemicals already
discussed (resveratrol, curcumin266-268) and more focused
drugs, such as metformin and rapamycin.266 Logically, it is a
moot point whether one might test resveratrol or any plant toxin
as a mimic of caloric restriction, or vice versa; understanding of
this interchangeability is evident in recent reviews.262,265 The
more general point, already touched on above, is that everyday
stresses, like light and plant toxins and hunger all, at low doses,
upregulate endogenous resilience pathways, and likely the
same pathways.
Independent Variables in What We Eat: Hunger Versus
Balanced Versus Toxic, Resilience-Inducing Supplements
Assuming plenitude, meaning no long-term lack of food or
vitamins or the required trace elements, several issues are
involved in the impact of what we ingest on health:
1. One is caloric restriction and its documented impact on
morbidity and mortality. Given the arguments proposed
above, we suggest that caloric restriction has its impact
because the metabolic stress of the restriction upregu-
lates resilience mechanisms.
2. A second is the concept of a balanced diet: holding
caloric intake constant and supplying vitamins and trace
elements—what balance of fats, carbohydrates, and
protein produces least morbidity and greatest longev-
ity? Studies on this balance in a range of species,
including humans, suggest a particular balance—low
(10%) protein and high carbohydrate.269
3. A third is the level of resilience-inducing toxins present
in the diet, as discussed above. This level can be
increased by choosing toxin-delivering foods (the Med-
iterranean diet) or with supplements, without affecting
either the level of hunger or the protein/carbohydrate/
fat balance.
There may be more such variables to consider, but these 3
seem important, and independent of each other, in analyzing
the impact of diet on morbidity and mortality.
Lack of Oxygen: Ischemia, Remote Ischemia,
Exercise-Induced Ischemia, Hypoxia
Mammals require a constant supply of oxygen. There is a tech-
nical term for it—we are “obligate aerobes.” Our tissues can
and do produce quantities of ATP from glucose without oxy-
gen, using the anaerobic glycolysis pathways inherited from
bacteria. The power of the oxidative phosphorylation pathways
is that they have evolved to act in series with glycolysis, com-
bining one of the end products of glycolysis (lactic acid) with
oxygen, to produce *10-fold more ATP from the same glu-
cose, and hence from the same meal.
This greater yield of ATP from oxidative metabolic path-
ways fuels the warmth and vigor of mammals, but the price for
this vigor is our utter dependence on inhaled oxygen. The
oxygen is delivered to our tissues via the pulmonary and sys-
temic circulations, but the delivery is what logistics engineers
call “just in time”. None of our tissues has evolved a way to
store oxygen (they have evolved a way to store glucose, as
glycogen) and the brain, the most oxygen demanding and oxy-
gen sensitive of our organs, starts to fail (we lose conscious-
ness) within seconds of strangulation. So the obligation of
obligate aerobes is to prevent—and if it cannot be prevented
to survive—a failure of oxygen supply and therefore any failure
of blood supply (ischemia).
Local Ischemia Induces Local Resilience
Our tissues can become short of oxygen—hypoxic—in several
ways. The most common are a blockage in the artery bringing
blood to them—ischemia, or a breach of the artery wall—a
hemorrhage. The tissue normally supplied by the artery lacks
a supply of oxygenated blood; it is said to be ischemic.
Figure 6. The study of caloric restriction can be traced back to the
1940s. It continues to increase, year by year.
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Prolonged ischemia causes death of the tissue affected, but if
the ischemia is partial or brief, the tissue survives and reacts in
self-protective ways.
The reports of Murry and colleagues270,271 pioneered under-
standing of the protective effect of brief ischemia. Their model
was the occlusion of one coronary artery (the circumflex) of the
dog heart for brief (usually 5 minutes) periods of ischemia,
separated by 5-minute reperfusion, simulating the transient
ischemia believed to cause angina pectoris; they also used
single, longer (30 or 180 minutes) periods, simulating a full-
blown heart attack.
Using a series of shorter periods, these investigators
tested271 whether the condition of the ischemic muscle deterio-
rated from the one 5-minute period of ischemia to the next;
would the effect be cumulative, resulting in muscle death? It
was surely a surprise when they noted that, while an initial brief
period of ischemia significantly compromised the muscle,
reducing its production of ATP and clearance of metabolites,
subsequent brief periods had little added effect. The muscle
somehow changed its state, stabilizing performance in the face
of repeated brief ischemic episodes, and no infarct formed.
From this limited observation, much has followed, for it
implied that sublethal ischemia was inducing resilience in the
muscle. To test this implication, the same investigators tested
whether the muscle was “conditioned” by brief (5 minutes)
occlusions, after which they applied a more sustained (40 min-
utes) occlusion, long enough—without conditioning—to kill
muscle and result in an infarct. Conditioning with several peri-
ods of sublethal ischemia reduced the size of infarct caused by
the 40-minute occlusion dramatically (75%). And when the
“test” occlusion was increased from 40 to 180 minutes, the
preconditioning did not reduce infarct size; the protective
effect seemed overwhelmed. These observations established
that sublethal ischemia can be very—but not infinitely—pro-
tective and raised many questions, tackled in subsequent
decades by several groups.271,272 And there were clinical impli-
cations, which these early authors foresaw:
. . .myocardial infarction often is preceded by multiple epi-
sodes of angina pectoris. It is possible . . . that patients who
experience repeated episodes of angina may similarly precon-
dition their myocardium . . . (and) alter the time course of cell
death after the onset of a sustained coronary occlusion. If this is
true, then the onset and early progression of cell death may be
slower in many patients than the results of animal studies have
suggested . . . . A slower progression of cell death implies a
longer window of time in which it might be possible to salvage
myocardium via reperfusion, e.g. with thrombolytic therapy or
coronary angioplasty.270
This prediction, that angina pectoris will prove to be protective
against a heart attack, has been confirmed many times and its
limits explored.273-276 The idea has been extended to other
organs examined both experimentally277 and clinically. For
example, transient ischemia of the brain protects the brain
against ischemic stroke,278 and transient ischemia of the retina
protects the retina against more sustained ischemia.279 All
these authors comment, in various ways, that the protection
they observe indicates the presence of endogenous, ischemia-
inducible protective mechanisms in the tissue under study.
At the molecular level, studies of the mechanisms of
ischemic conditioning have been reported for 2 decades. Early
in this period, Barone and colleagues277 reported that, during
conditioning ischemia of rat brain, the expressions of
interleukin-1 receptor antagonist messenger RNA (mRNA) and
protein were increased and the expression of c-fos was reduced.
Li and colleagues280 examined the effect of sublethal ischemia
to the retina on the expression of heat shock protein (HSP)-27,
HSP-70, and HSP-90, reporting a marked (2-fold) increase in
the expression of the mRNA and protein of HSP-27. Kawahara
and colleagues281 undertook a “genome-wide” microarray
analysis of ischemic conditioning in the rat brain, with several
experimental groups. The authors noted that protective
ischemic conditioning was associated with the upregulation
of transcription factors, including c-Fos, Hsp-70, and MAP
kinase-related genes, and neuronal death was associated with
upregulation of proapoptotic genes and downregulation of
genes implicated in survival mechanisms, which they identified
as including the MKKPI4 kinase and DAG/PKC pathways. At
a more general level, they noted that, following sublethal ische-
mia, 246 of the 8799 genes available in their arrays were upre-
gulated and another 213 downregulated. Viewed in this broad
way, the molecular response of brain tissue to sublethal ische-
mia is complex, involving several pathways, and difficult to
summarize. Writing in 2011, Morris and colleagues124 focused
on one family of genes, the sirtuins, and emphasized evidence
that these are involved in the tissue-protective effects of sub-
lethal ischemia and also of resveratrol (reviewed above) and of
caloric restriction (also reviewed above). Their analysis partic-
ularly notes the role of sirtuins in maintaining mitochondrial
function, influencing cell metabolism and survival/death, the
evidence deriving from work on species from yeast to mam-
mals, and emphasizes how several forms of stress can activate a
particular (key) family of genes. Brooks and Andrews’ 2013
review272 of the mechanisms of ischemic conditioning of heart
muscle had a different emphasis. Their description highlights
the release of cytokines (bradykinin, adenosine, and opioid
peptides) from heart muscle made briefly ischemic and their
role in triggering a “cascade” of intracellular pathways via
receptor activation of membrane-bound G-proteins. Proteins
generated by these pathways converge on the inner mitochon-
drial membrane where they reduce the generation of reactive
oxygen species. They also summarized pathways that induce a
period of delayed (by 12-24 hours) protection of heart muscle
following brief ischemia. The same endogenous cytokines that
mediate the short-term protective response activate nuclear
transcription factors (they identify NF-kB, AP-1, and HIP-
1a), triggering the synthesis of known mediators of tissue pro-
tection (iNOS, COX-2, aldose reductase, HSP, and Mn-SOD).
It is this process of protein synthesis that, these authors suggest,
delays the protection provided by these pathways. The sirtuins
were not mentioned in this analysis.
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As with PBM and the phytotoxins, it would seem that the
mechanisms of ischemic conditioning are multiple and difficult
to summarize. Among the factors common to them are that
resilience is induced by low levels of stress and that higher
levels of the same stress are tissue destructive.
“Remote” Ischemia Induces Resilience at a Distance
Ischemic conditioning does not provide an attractive path to
therapy; there has been no move to induce brief ischemia in a
threatened organ, in the heart, for example, to protect it from
later damage. A pathway to therapy did seem to emerge
when investigators282 noted that ischemia of part of the
heart (brief closure of one coronary artery) induced a pro-
tective response throughout the heart. An unsuspected
mechanism was spreading the benefit from a patch of
ischemic heart muscle to the whole heart. How far could
this benefit of brief ischemia spread?
This founding observation of “remote ischemic con-
ditioning”282 (RIC) has been confirmed and expanded (Figure
7) in many configurations. In the laboratory and in small clin-
ical trials, brief ischemia of one limb, for example, has been
shown to protect the brain,283 lung,284 kidneys, liver, skin flaps,
intestines,285,286 and retina,287 as well as the heart, from sub-
sequent damage. Further, the protection provided by remote
(usually limb) ischemia functions against not only ischemia
but against other forms of damage—for example, protecting
retinal neurones from axon damage288 and LD,289 as well as
from ischemia.287 Further, RIC is not specific to a particular
tissue; in small clinical trials, brief ischemia to a limb has been
reported to be protective to the heart, lung, and brain290; the
protective pathways are present in the genome of every cell and
therefore every tissue. Still further, the effect of RIC on other
tissues may go beyond protection. Brandli and colleagues156
reported, for example, that brief limb ischemia causes a 10% to
15% supernormality in the electroretinogram. The phenotypes
of stress-induced tissue resilience are discussed below; stress-
induced supernormal function has been described for muscle as
well as retina.
This evidence that “remote” (usually limb) ischemia induces
body-wide resilience and even supernormal performance has
led (as with other stressors) to a search for mechanisms, driven
partly by the need to understand, and partly by the need to be
sure that the effects are identifiable at the molecular level, for
they seem “too marvelous” in vivo. As with light and the phy-
tochemicals and hunger (above) and exercise (below), the
search has yielded a rich range of candidates. In reviewing this
profusion, Pickard and colleagues286 noted that the pathways of
RIC must involve a reaction in the tissue-made ischemic, then
pathways—neural and/or humoral—connecting the ischemic
tissue to tissues in which protection is assessed, and finally a
reaction (more pathways) in the tissues made resilient. In the
case of limb ischemia-induced cardioprotection, they summar-
ized evidence that adenosine released by ischemic muscle acti-
vates small-diameter sensory fibers serving the muscle in a
spinal reflex, for which the output pathway may be parasym-
pathetic supply to the heart. And they noted evidence that the
cardioprotective effect is partly or wholly mediated by blood-
borne factors, including opioids, cannabinoids, and transcrip-
tion factors such as HIF-1a. In more recent studies, discussed
above in the context of the remote effects of PBM and reviewed
by Kim et al,52 a third mechanism of remote conditioning is
emerging—the mobilization of bone marrow–derived “stem
cells”53 or Myo/Nog cells. There is no lack of candidate
mechanisms; all deserve further investigation.
In humans, recent clinical trials give evidence that RIC can
improve neurological outcomes in stroke291 and aneurysmal
subarachnoid hemorrhage292; can improve the microcirculation
of skin flaps used in reconstructive surgery293; can protect
heart, lung, and liver function during heart valve surgery294;
and can reduce infarct size in myocardial infarction (heart
attack).295
Results of trials have not been uniformly positive, however.
Although no investigators have reported RIC to be damaging,
in several trials and meta-analyses, investigators have reported,
for example, that RIC had no beneficial effect in heart attack296
or heart valve surgery297 and failed to improve kidney function
after transplantation.298 In a large-scale and recent meta-
analysis, Benstoem and colleagues299 concluded that no bene-
ficial effect of RIC survived the analysis, which included many
protocols of RIC, many analyses, many outcome measures, and
many apparently promising smaller studies. The promise of
RIC seemed elusive, too open to observer bias, small numbers
of trial participants, and inadequate statistical testing.
This contrast between the promise of laboratory studies and
small clinical trials, on the one hand, and lack of promise
indicated by meta-analyses of the clinical trials, on the other,
has not slowed interest in RIC (Figure 7). Investigators have
approached the disappointment of the larger analyses in 2
ways: (1) They have searched for details of pathway regulation
by RIC. Nikkola and colleagues,300 for example, compared
whole-blood transcriptomes using RNA sequencing and
genome-wide DNA methylomes before and after RIC,
Figure 7. Evidence of the growing interest in remote ischemic
conditioning.
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identifying >130 differentially expressed genes and almost
3500 differentially methylated CpG sites, which overlapped
with >100 of the differentially expressed genes. Further, the
differentially expressed and methylated genes formed part a
tightly coexpressed group of genes related to cell cycle path-
ways and inflammatory responses. The outcome gives “hard
evidence” mechanistic support for the positive clinical out-
comes. And (2) Investigators have begun or encouraged299,301
the search for “confounding factors.” Rather than accept the “no
real effect” neutrality of meta-analyses, they have begun to
search for reasons why large-scale analyses are leading to con-
clusions of “no effect.” The most common explanation proffered
by meta-analysts for their negative conclusions has been that the
pioneering studies were biased or underpowered. In response,
the pioneering researchers are beginning to ask whether the
larger analyses might (or not) have a tendency to bury the prom-
ise of the smaller studies in unidentified heterogeneity.
Is Hypoxia the Key Stress of Ischemia-Induced
Tissue Protection?
Hypoxia can and does occur without ischemia and, if severe
and prolonged, is quickly fatal. The question arises and has
been addressed, whether brief or partial hypoxia without ische-
mia can induce tissue resilience like that induced by low-dose
ischemia and remote ischemia. The answer to the question is
affirmative. For example, Zhu and colleagues reported in work
on rats that sublethal hypoxia (11% inspired O2), without any
blockage to blood flow, induces the same protection of the
retina as sublethal ischemia.259 Barrington and colleagues302
specifically compared ischemic with hypoxic stress in healthy
men, noting essentially similar upregulation of HSPs. A recent
review of the value of hypoxic conditioning for the protection
of the CNS303 traced many studies of this issue. In animal
studies, for example, hypoxia in adult rats increased hippocam-
pal neurogenesis304 and, given after experimentally induced
stroke, increased hippocampal neurogenesis and mitigated
memory loss.305-307 Hypoxic preconditioning (exposure to
hypoxia before an induced experimental stroke) also mitigated
structural loss,308-310 reducing the size of the infarct by as much
as 50%. These effects involved, or at least were associated
with, regulation of a number of pathways, including the expres-
sion of HIF-1a and its target genes (erythropoietin, vascular
endothelial-like growth factor).309,311-313
Two forms of hypoxia have been well studied clinically. In
humans suffering the hypoxia of sleep apnea, Lavie and
Lavie314 reported that, while severe apnea in humans was asso-
ciated with higher morbidity and earlier mortality, chronic
“mild” apnea, causing correspondingly mild hypoxia, was
associated with reduced morbidity and delayed mortality, less
than in apnea-free controls. In the second form, more often
regarded as an adventure than an experiment, humans volunta-
rily subject themselves to hypoxia as passengers or crew on
airlines or as athletes training at high altitude. The outcome of
these latter situations has been much studied but, as far as we
can tell, not with the idea of hypoxia-induced tissue resilience in
mind. Airlines are concerned for the immediate welfare of pas-
sengers, and athletes and their coaches seek enhanced perfor-
mance in imminent competition. There is evidence of overall
reduced morbidity and delayed mortality in long-term air
crew,315-317 compared to general populations, despite raised
incidences of death rates caused by flight accidents and some
cancers. All studies noted flight crew-specific factors, including
the health requirements for admission to crew status, irregular
working hours, greater exposure to exhaust fumes, and incident
radiation, but not the possible resilience effects of repeated expo-
sure to mild hypoxia. Perhaps the clearest observation was that
of Linnersjo and colleagues’ report of lower incidence of myo-
cardial infarction and mortality during the pilots’ flying career
and beyond. This literature is limited, but the number of people
who experience the mild hypoxia of airline flight (most flights
are pressurized to the equivalent of 8000 ft altitude, at which the
partial pressure of oxygen is 25% less than at sea level) is enor-
mous, approximately 3 million per day. There may be much still
to be learned from this daily “experiment.”
Summarizing, there is limited but so far uncontradicted evi-
dence that mild hypoxia induces protective effects comparable
to those induced by ischemia; hypoxia may be the key
resilience-inducing element of ischemia.
Excess Demand: The Resilience Induced by Exercise
The understanding that exercise is healthful goes back millen-
nia, to the writings of Hippocrates in the Western tradition and
of Susruta in the Indian tradition. Histories of the understand-
ing can be traced from elsewhere318-320; the literature is con-
siderable. By contrast, understanding of the mechanisms of that
healthfulness, and of why the mechanisms evolved as they
have, is recent and incomplete. One way of understanding both
the mechanisms and their evolution is to view exercise as an
everyday stress that induces hypoxia in muscle, activating the
mechanisms identified in experimental work on direct and
remote ischemia of muscle and on hypoxia (above).
The recent literature on exercise has shown the same rapidly
increasing pattern seen for light and food—a year-after-year
growth since the 1990s (Figures 8 and 9). In these studies,
hypoxia in muscle is rarely measured; instead, the level of
exercise is measured or the accumulation of the products of
anaerobic glycolysis assessed, for example, as lactate levels in
blood. The phenomenon already discussed of RIC suggests that
the benefits of exercise are mimicked by making one limb
ischemic, that the oxygen debt induced by increased demand
is the key element in exercise-induced tissue resilience. Put
more simply, exercise is good for us because it makes our
skeletal muscle hypoxic, and the muscles respond by releasing
identifiable “myokines,”321,322 whose actions include the upre-
gulation of endogenous mechanisms of tissue resilience.
Exercise and Cancer
A great deal of interest has centered on the value of exercise in
the treatment and management of cancer, with hundreds of
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studies and reviews published, at a steadily growing rate (Fig-
ure 8). There seems to be wide agreement that exercise can
improve the quality of life and the psychological and physical
strength of patients with cancer undergoing therapy323-325 and
can counter the side effects of therapy, for example, of andro-
gen deprivation therapy in men with prostate cancer.326 A
smaller number of studies report evidence that exercise can
prevent onset or recurrence of cancers (eg, Adraskela et al and
Friedenreich et al327,328). Understanding of the mechanisms of
exercise-induced resilience to cancer has been approached in
several ways. One intriguing line of work has suggested that
exercise upregulates the immune and anti-inflammatory sys-
tems, mobilizing natural killer cells,329,330 recruiting the antic-
ancer potential of these systems. At the molecular level, Coyle
and colleagues331 have reported evidence that exercise in
women reduces promoter hypermethylation of tumor suppres-
sor genes, such as APC, in nonmalignant breast tissue; hyper-
methylation of the promoter is considered to suppress
expression of the gene, so making the formation of a tumor
more likely. Sanchis-Gomar and colleagues332 have suggested,
more generally, that the anticancer effects of exercise may be
exerted by epigenetic modulation, that is, by regulating expres-
sion of the genome through methylation of genes, and they
borrowed the term “eustress” to denote stress that induces
healthful epigenetic changes. Other authors333 influenced by
knowledge that—for many cancers—age is a major risk factor
and by growing evidence that the immune system is an effec-
tive defense against cancer, have reviewed studies that show
that exercise slows immunosenescence, the slow loss of
immune function associated with age. At least some of the
anticancer effect of exercise, these studies suggest, may be
exerted via the maintenance of immune function.
Exercise and Cognition
Exercise (voluntary wheel running) mitigates the loss of hip-
pocampal neurogenesis and of maze learning in aging
wild-type mice.334 Exercise, when trialed in mouse models of
Alzheimer disease—usually transgenic strains that develop the
Ab and tau pathology of that condition—has been shown to
decelerate that pathology335-337 and to mitigate the associated
cognitive loss and loss of transmitter-related enzymes. The
effect is robust, reliable, and, measured as the level of soluble
Ab in the hippocampus, is dose dependent.338 The effect has
provided a starting point for further, striking observations. In
one follow-on observation, for example, Herring and col-
leagues339 reported that exercise in the pregnant mother slows
the development of the Ab plaque pathology of her progeny,
suggesting epigenetic transmission of the effect for at least one
generation (and another challenge for human mothers deter-
mined to have the perfect baby). Fragoso and colleagues340
provided a confirming observation that maternal exercise dur-
ing pregnancy in rats attenuates the damage to the fetal brain
caused by malnutrition.
For reasons argued elsewhere,220 we suggest that, in these
transgenic models of dementia, exercise may act by preserving
the structural integrity of cerebral vessels, which are weakened
by the transgenes. These transgenes are derived from human
mutations that cause early-onset dementia and early-onset
stroke (see, eg, Figure 2 in the study by Kumar-Singh
et al341). The importance of vessel integrity in the exercise-
induced mitigation of cognition is supported by the observation
that the gene most powerful in regulating susceptibility of age-
related dementia in humans (APOE) is critical for the effect of
exercise in protecting the integrity of the “neurovascular
unit.”342 And several studies, reviewed by Rzechorzek
et al,343 have directly linked exercise to the preservation of the
integrity of cerebral vessels.
The above observations of the protective effect of exercise
on cognition in rodents have been translated to humans. Several
authors have reported that moderate exercise (eg, two
20-minute bouts of cycling per week344) improves cognitive
performance in patients with mild cognitive impairment, an
improvement that was enhanced by cognitive enrichment and
Figure 9. Recent growth in published studies on the impact on exer-
cise on cognition and on Alzheimer’s disease.
Figure 8. The growth in studies published on the relationship of
exercise to chemotherapy or radiotherapy.
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faded if the exercise was not persisted with. By 2017, Saez de
Asteasu and colleagues149 were able to review 26 randomized
control trials, testing the effects of exercise on cognition, but
now seeking to identify which forms of exercise were more or
less effective. Searching for mechanisms, Dinoff and col-
leagues345 undertook a meta-analysis of 55 published studies
of the effects on exercise on blood levels of brain-derived
neurotrophic factor (BDNF), confirming that exercise induces
increases in plasma levels, in a dose-related relationship.
BDNF is one of the “myokines” (molecules released by exer-
cising muscle into the bloodstream) and one of the most pro-
minent factors identified in studies of the mechanisms of
resilience induced by exercise and the other interventions con-
sidered here.24,178,289,346-349 In a meta-analysis of 35 studies of
humans with chronic diseases, Cai and colleagues350 reported
that their analysis suggests that “exercise interventions posi-
tively influence cognitive function . . . independent of the type
of disease (and) . . . of the type, frequency and intensity of
the . . . intervention.”
Exercise and Aging
The literature on exercise and aging is fast-growing, raising the
questions whether resilience fades with aging and whether that
fading can be mitigated.
Resiliosenescence? Frailty—the opposite of resilience—is the
common experience of aging humans. Our skin tears more
easily and heals more slowly, our muscles weaken, we bounce
back less readily from falls and disease. Intellectually, though
we may long maintain cognitive performance, our “cognitive
margin” shrinks; in a high fever, the old become delirious more
easily and recover more slowly. The examples are too many to
allow documentation, but several theories of aging are cur-
rently debated— “rate of living” or “oxidative damage”259 or
the shortening of telomeres.
So far, the evidence is clear, as far as it goes. The low-stress-
resilience response—and therefore resilience—fade with age
and the fading can be slowed or stopped with low-level stress.
Power and colleagues351,352 reported that the number of motor
units in muscle (they examined the tibialis anterior muscle of
the leg) declines with age and that the decline is less in
“masters” running champions, so maintaining muscle strength
closer to youthful levels. Soto and colleagues342 reported that
in mice the structural integrity of cerebral vessels declines with
age (with loss of basement membrane and pericytes and break-
down of the blood–brain barrier), and that the decline is miti-
gated by long-term aerobic exercise, and further that the
mitigation is dependent on the APOE gene, known to be an
important regulator of age-related dementia in humans. Rze-
chorzek and colleagues343 reported that the pial circulation
becomes “rarified” and the severity of stroke increases in aging
mice and that both age-related changes are mitigated by aerobic
exercise. Dimauro and colleagues353 reported that regular exer-
cise in human patients suffering type 2 diabetes mitigated the
shortening of telomeres and other measures of DNA damage in
leukocytes taken from their blood and reduced levels of apop-
totic cell death in their lymphocytes. The observation that exer-
cise mitigates the damage to DNA associated with age—
telomere shortening and oxidative damage—has enjoyed con-
siderable recent confirmation.354-356 Correspondingly, one of
the intriguing resilience responses of the heart—angina-
induced protection against infarction—is lost in the elderly
patients, except in a subcohort that exercised regularly.273,274
These specific observations for aging and exercise, taken
together with the evidence that caloric restriction slows aspects
of aging (above), that saffron as a dietary supplement and PBM
can slow, even partially reverse the age-related degeneration of
the macula region of the retina,31,243 suggest that loss of resi-
lience is a factor, not previously recognized but of major
importance, in the biology of aging. Put another way, when
one catalogs the interventions known from rigorous studies to
slow the gathering frailties of age, they include not only exer-
cise and caloric restriction (most clearly) but also plant toxins
and PBM—stresses that induce the more acute resilience
responses discussed above. Resilience, like acquired immunity,
fades with age and the loss can be mitigated by the daily low-
level stress of exercise or (at least for resilience) by a slightly
toxic diet or caloric restriction or PBM.
Physical Stresses
One further group of stresses needs to be considered—the
physical/ mechanical stresses of temperature, external abra-
sion, and even (and especially) the stresses of pulsatile blood
flow on our blood vessels.
Heat
The literature on the effect of low-level heat stress on animal
tissues is very considerable. It is older than the literatures on
phytochemicals and seems more mature: Rates of publication
been very high but have plateaued or even fallen in recent years
(Figure 10). The move to clinical trials has commenced, though
it has been late in coming; there has presumably been hesitation
to use heat to condition patients for surgery or to slow degen-
erations. It was the study of the response of tissues to moderate
heat (for mammalian tissues up to 42C) that pioneered the
identification of a major mechanism of stress-induced resili-
ence, the HSPs, and the transcription factor that regulates their
expression (heat shock factor 1).
As more was learned about HSPs, it became evident that,
although they were first named after their upregulation by low-
level heat stress on cells in culture or in nonmammalian organ-
isms, they are highly conserved from yeast to mammals.357,358
Further, they are upregulated, not just by heat, by a range of
stresses and—arguably—had been better dubbed “stress
shock” proteins.359 Their tissue-protective effects derive from
the effectiveness of HSPs as chaperones for proteins, ensuring
the correct folding of proteins as they are formed, the repair of
damaged proteins, and the stability of proteins already
formed.357,359 They have been recognized in many studies as
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playing a role in the tissue-protective effects of several of the
interventions considered above: plant toxins,360-362 caloric
restriction,363,364 and hypoxia and exercise.365,366 Further, the
failure of the heat stress response (ie, the failure of cells to
upregulate their expression of HSPs in response to stress)
appears to be a factor in aging367 and therefore in the trend
already reviewed above for tissue resilience to fade with age.
Reinforcing the idea that HSPs are important in tissue resi-
lience generally, they are reported to be effective in slowing
muscular dystrophy in a rat model,368,369 in slowing the devel-
opment of cortical pathology in a rodent model of demen-
tia,370,371 in mitigating the tissue pathologies of diabetes,372
in protecting the failing heart,373 in reducing neuroinflamma-
tory markers in astrocytes, and in conditioning of cardiomyo-
cytes374 and fibroblasts375 in vitro. In short, HSPs are
upregulated by a range of stresses and are protective to a range
of tissues, ranges comparable those of the inducers of resilience
and of tissues protected, considered in previous sections.
Cold
The question whether moderate levels of cold also induce resi-
lience in body tissues remains unsettled. Cold-shock proteins
were first described in plants,376 in work that focused on a
comparison between plant responses to heat and cold; it was
concluded that the response to cold was distinctive, with no
homology to the response to heat. Cold-shock proteins were
identified in mammals a decade later,377 including a cold-
specific CIRP (cold-induced RNA-binding protein). Fujita and
colleagues suggested that CIRP, like HSPs, acts as a protein
chaperone, maintaining, in this case, the stability of RNAs in
the face of stress. Al-Fageeh and Smales378 reviewed detailed
molecular mechanisms of the mammalian response to cold.
Recent reviews and reports suggest, however, that the protec-
tive effect of cold, at least for the oft-studied traumatized CNS,
arises not from an upregulation of endogenous protective path-
ways (such as HSP expression379) but from a downregulation
of metabolic demand.380
In recent years, several studies have addressed with the
question whether cold can condition tissues to a subsequent
stress. The evidence seems mixed on this point. Cold acclima-
tization of humans was reported, for example, not to mitigate
cognitive loss to subsequent exposure to cold.381 On the other
hand, Qin and colleagues382 reported that “mild” hypothermic
preconditioning of liver cells (exposure to 26C for 3  10
minutes) preserved the viability of the cells, after they were
cooled to 4C for storage. Overall, work on cold conditioning is
at a relatively preliminary stage.
Mechanical Injury: The CNS and the Vasculature
Evidence has been observed of resilience induced by mechan-
ical damage in the CNS. Wen and colleagues349 reported a
finding that was surprising at the time. They were studying the
ability of growth factors injected into the vitreous humor of the
rat eye to slow an inherited photoreceptor degeneration; they
were pioneering then-new approaches to mitigating retinitis
pigmentosa. As a control for the mechanical effect of the injec-
tion, they observed that simply inserting a needle (not loaded
with a growth factor) through the retina into the vitreous humor
slowed the death of photoreceptors for over 1 mm around the
point of penetration of the retina. They associated this protec-
tion of photoreceptors with the upregulation of particular
growth factors (CNTF and bFGF). This observation influenced
Purushothuman and colleagues383 to examine the status of cer-
ebral cortical tissue surrounding a needlestick lesion in the
healthy, young brain. The lesion was made to test whether the
small associated hemorrhages led to the formation of Ab-rich
plaques, like senile plaques in the human brain. They did, but in
the regions flanking the needlestick track (up to 1 mm away),
these authors reported a transient upregulation of the expres-
sion of Ab intraneuronally, of oxidative damage to nuclear
DNA, and of hyperphosphorylation of the cytoskeletal protein
tau, but no neuronal death. They suggested that, for several
days after the needlestick injury, nearby cortical tissue upregu-
lates endogenous protective pathways, in which Ab plays a
protective role. These observations have implications for the
understanding of the degenerating CNS; they imply, for exam-
ple, that each plaque in the dementing human brain may be
surrounded by a sphere of resilient tissue, its resilience explain-
ing the year-long course of dementia in many patients.383 These
Figure 10. Publications (above) and reports of clinical trials (below)
mentioning heat-shock proteins in their title or abstract, from PubMed
at May 2018.
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observations on the CNS remain few, however, and raise ques-
tions. Within the heart, for example, localized ischemic stress
induces resilience throughout the heart,282 whereas in the brain
and retina, the spread of resilience from a site of damage
appears to be in the order of a millimeter. In both tissues (CNS
and heart), protection spreads from a site of stress, but over
very different distances; factors determining the spread deserve
investigation.
By contrast, very considerable work has gone into identify-
ing the response of the vascular endothelium, especially of
arteries, to another mechanical stress—the shear stress created
by the flow of blood over the endothelium. Recent studies have
sought to identify how the endothelial cells sense the shear
stress of blood flow384; to define mechanosensitive networks
involved,385,386 especially where flow is “complex” and ather-
osclerotic plaques are likely to form387; and to follow the invol-
vement of HSPs in shear-induced responses of endothelial
cells.388
Despite the richness of this literature, however, a direct link
from shear stress on endothelial cells to HSP expression to the
resilience of blood vessels has not been defined, although the
work of Adams and colleagues389,390 comes close to demon-
strating it. Working in a pig model of ventricular fibrillation,
they exposed the anesthetized animal to mechanical head-to-
foot shaking, at frequencies designed to create a sinusoidal
shear stress on endothelial cells of blood vessels, additional
to the pulse. They applied this shaking prior to inducing ven-
tricular fibrillation and then recovery from fibrillation
(mimicking a heart attack and recovery). The preconditioning
shake improved the viability of the myocardium after the
experimental fibrillation and defibrillation. This approach
remains at the experimental stage, but it does contribute one
step in the link from shear stress to pathway upregulation to
tissue resilience.
Understanding Stress
Steps and Missteps in Understanding Hormesis
Concepts can be defined. A recent definition of hormesis can
found elsewhere,108,391 where Mattson proposed that hormesis
is a term used by toxicologists:
. . . to refer to a biphasic dose-response to an environmental
agent characterized by a low dose stimulation or beneficial
effect and a high dose inhibitory or toxic effect.
Or, more briefly, Calabrese and Baldwin392 described
hormesis as:
. . . a dose-response relationship phenomenon characterized by
low-dose stimulation and high-dose inhibition
Concepts are perhaps best understood, however, by their his-
tory, controversies, and explanatory power. The idea of horm-
esis is sometimes traced to the Swiss scientist, physician, and
astrologer Paracelsus (1493-1541), whose writings, in many
fields, are best known today for one maxim—
Alle Dinge sind Gift, und nichts ist ohne Gift, allein die Dosis
macht dass ein Ding kein Gift ist.393 (All things are poison, and
nothing is without poison, the dosage alone makes it that a thing
is not a poison)
—which he formulated to defend his use of inorganic chemi-
cals in the treatment of his patients. Historians of toxicology
(eg, the study by Borzelleca394) regard Paracelsus as a founder
of the field, because he drew attention, early in the Renais-
sance, to the importance of dose–response relationships. Para-
celsus’ maxim, though influential, does not capture the most
intriguing feature of the low-dose zone of dose–response rela-
tionships—that many “Dinge” regarded as toxins not only lose
their toxicity at low doses but are tonics, evoking positive
tissue responses. This realization came in the late 19th century,
formulated as the Arndt-Schulz rule. In Wikipedia, the rule is
stated as:
For every substance, small doses stimulate, moderate doses
inhibit, large doses kill.
In a medical dictionary (http://medical-dictionary.thefreedic-
tionary.com/Arndt-Schulzþlaw), it is stated as:
. . .weak stimuli accelerate physiologic activity, medium sti-
muli inhibit physiologic activity, and strong stimuli halt phy-
siologic activity.
And from there followed a series of missteps, which must be
understood, lest we extend the series. One early misstep has
been laid at the feet of Hugo Schulz, because he saw low-dose-
positive responses as the explanation of the then-popular doc-
trine of homeopathy and pursued the idea through his career. A
second misstep was, Calabrese has argued,395 an overreaction
to Schulz’ confidence in the efficacy of extreme low doses; it
was to accept Paracelsus’ view that dosage is of major impor-
tance, yet ignore the low-dose-positive phenomena, because
of their association with homeopathy. Interest in the low-
dose-positive zone of the dose–response curve of toxins was,
Calabrese argues, set aside for decades, until the idea was
picked up again, in the middle of the 20th century396 in a
nonmedical context.
This set-aside was not a trivial omission. Stress is commonly
assumed to be a cause of ill-health, not health. On this assump-
tion, epidemiologists have long extrapolated rates of cancer
induction in healthy tissue by low doses of known carcinogens
from high-dose effects. Recently, however, this “linear no-
threshold” model has been declared dead99; evidence has been
gathered that low-dose exposure to radiation is protective
against cancer397 and neurodegeneration,100 and some have
argued that low-dose radiation could be employed to prevent
cancer.398 And conversely, drugs used to kill cancer cells in
vivo (chemotherapy drugs) at a high dose (usually the highest
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dose that doesn’t kill the patient) have the opposite effect at low
dose, encouraging the viability/proliferation of cancer cells.399
Current approaches to both carcinogens and chemotherapy
still, Calabrese argues, too often ignore the implications of
these low-dose effects. The practical question arises, for exam-
ple, whether, as a chemotherapy drug is cleared from the body
at the end of each cycle of chemotherapy, there is a period
during which the drug at low concentration partially reverses
its good work of killing the tumor. The question may or may
not change the practice of chemotherapy, but it deserves an
answer.
The story of the rerecognition of low-dose-tonic responses is
of interest. Southam and Ehrlich396 described the effect of an
extract from the wood of the Western red cedar tree on invasive
fungi. It was Southam’s research project in forestry, done in the
midst of World War II (Figure 11). Southam later studied med-
icine and published in the area of antibiotics and bacteria (for a
very readable account, see http://dose-response.org/chester-m-
southam/). Southam’s data showed that a hot water extract of
the wood is toxic to the fungi, but when he diluted the extract
successively, to construct a dose–response curve (as Paracelsus
would have recommended), low concentrations of the same
extract stimulated growth of the fungi. So, the tree had evolved
a chemical to deal with the fungi and the fungi had evolved a
mechanism to use low doses of the toxin to upregulate their
reproductive pathways. Southam and Ehrlich396 did not argue
this evolutionary interaction—that idea came later. But they
did suggest a new term:
The term hormesis (adj. hormetic) is proposed to designate such
a stimulatory effect of sub-inhibitory concentrations of any
toxic substance of any organism.
The interaction between the tree and the predatory fungi
seems comparable to the interaction between vegetables and
predatory animals, in which animals have evolved a dual
response. One response, as Mattson and colleagues108,400 have
pointed out, is to evolve toxin-metabolizing pathways to clear
the toxin quickly. The second is to evolve pathways that use the
toxins to upregulate resilience pathways, so that low doses of
the toxins act as tonics. The first of these responses has long
been recognized and termed “tolerance.” It is the second
response that Arndt and Schulz observed in the late 19th cen-
tury and Southam, in the mid-20th century, called hormesis.
The response is modest and counterintuitive and readily mis-
interpreted. The reader can assess the still slow recognition of
its importance in the accounts given above of the resilience
induced at low doses by sunlight, phytochemicals, ischemia
and exercise, caloric restriction, and mechanical or thermal
damage to tissues, that is, by the stresses of everyday life.
As so often in the recognition of biological systems, evolu-
tion provides the conceptual framework for understanding.
Organisms that adapt survive; the adaptation between plants
and animals is typically interactive108 and, when we understand
the interaction, we also understand another mechanism evolved
by animals to survive, and we can make the stresses tools in our
struggle for individual health and longevity.
The concepts of dose–response and hormesis will likely
continue to evolve. Sanchis-Gomar and colleagues332 have
recently restated the idea of hormesis as “eustress,” a level of
stress that, through epigenetic mechanisms, induces healthful
responses body-wide; the term eustress came (as the authors
acknowledge) from earlier workers. Their contribution was in
the context of the beneficial effects of moderate exercise on
mortality and many forms of morbidity. They did not mention
hormesis or its history as an idea. Murugaiyah and Mattson108
recently argued (and see above) that the interaction between
plants and herbivores has evolved through several steps, shown
in their Figure 1, each “side” in the struggle developing new
weapons during long battles. In terms of evolution, the process
is adaptive, the plants evolving successive ways to deter and
herbivores evolving successive ways to evade the deterrence.
These authors argued that hormesis plays a central role in evo-
lution and, conversely, that evolutionary pressures have had a
central role in the development of hormesis.
More generally, Murugaiyah and Mattson108 have argued
that the concept of hormesis applies not just to toxins but to
other stresses. They identify exercise and caloric restriction and
make out a strong case for their role in eliciting “positive”
tissue responses. We here extend the idea to include ischemia
Figure 11. From Southam’s research thesis (1941), the origin of the term hormesis (http://dose-response.org/wp-content/uploads/2002/01/So
uthamThesis1941.pdf). The change of “toxicotrophism” to “hormesis” is, of course, Southam’s.
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and remote ischemia, sunlight (especially PBM), and mechan-
ical or thermal damage, so to the several classes of everyday
stress mentioned at the beginning of this review.
The Explanatory Power of a Concept
Good new ideas, it has been said, rapidly seem obvious. Horm-
esis, to those of us writing in the area, has that quality. That the
idea has long been partly understood, partly misunderstood, too
long ignored becomes apparent when its explanatory power is
examined in specific examples.
Hair Removal and Hair Growth
Hair management is not the most serious of medical issues
but—for cosmetic reasons—folk seek both to eliminate hair
and to encourage its growth, and use light energy, in many
cases of the same wavelength, for both purposes. At high
energy, laser-sourced red–infrared energy will destroy a hair
follicle permanently; the technique is long established. Con-
versely, low-energy laser-sourced irradiation of the skin pro-
motes hair growth.11
Light Conditioning and LD to the Retina
The complex relationship between light and the vulnerability
of rod and cone photoreceptors to damage (discussed previ-
ously) is also best understood in terms of hormesis. As noted
above (in section “White Light”), even low levels of light
damage the outer segments of light-naive rods, which become
shorter, less sensitive, their beautifully folded membranes
becoming disrupted and irregular. Yet, without some level
of light experience and damage, the photoreceptors are deva-
stated by bright daylight.81 The normal state of photorecep-
tors is that they are both damaged and made resilient by
normal exposure to light.
Ab, Alzheimer Disease, and an Insight Into
Neuroprotection
This is an issue of major clinical importance. For some
decades, the most widely accepted view of the cause of age-
related dementia has been the amyloid cascade hypothesis,
which posits the cause in proteinopathies, abnormalities of 2
molecules expressed prominently in the brain, the peptide Ab,
and the protein tau.401-403 In this understanding, a “chronic
imbalance in the production and clearance of Ab” as the brain
ages results in the accumulation of various forms of the pep-
tide and eventually in its deposition in an insoluble form,
demonstrably present in senile plaques. Although the mono-
meric peptide and deposited insoluble forms appear not to be
toxic, intermediate, oligomeric forms are considered toxic to
the membranes of surrounding neurones, damaging synapses
and killing neurones.404 The damage spreads until the brain is
riddled with sites of deposition of the peptide, the plaques that
Alzheimer and his contemporaries observed, and of
hyperphosphorylated forms of tau, a protein that forms part
of the internal skeleton of neurones. Further, “all of the
genetic events currently known to predispose to the develop-
ment of AD act to alter the economy of Ab in brain tissue.”404
Mutations that cause familial forms of the dementia are all
found in APP, the gene that generates the precursor protein
APP, from which the peptide Ab is excised, or in the enzymes
that perform the excision. Further, APP is found on chromo-
some 21 and a trisomy of 21 causes a syndrome (Downs) in
which, inter alia, the same brain pathology is found. The
amyloid cascade hypothesis remains widely debated,405 and
clinical trials of antiamyloid drugs continue to attract invest-
ment, if not success.
In more recent years, others have predicted406 and then
reported evidence407,408 that, when attention was given to the
effects of lower doses, Ab is neurotrophic, enhancing synapse
formation and memory-related LTPs, upregulating antioxidant
mechanisms, and inhibiting microbial infections.409 From this
work, the long-elusive physiological role of Ab (Why would
the brain have evolved to secrete a self-destructive molecule?)
seems to be emerging: It is a self-protective molecule, upregu-
lated by stress. Other questions remained. It was already known
that the constitutive expression of Ab is higher in the brain than
in other organs410 and that its expression in the brain is upre-
gulated from this relatively constitutive high level by
stress.405,411 So, what is special about brain tissue that has led
to the evolution to this brain-prominent form of stress-
inducible self-protection? Kuo and colleagues described the
preferential binding of hemoglobin to Ab.412,413 This binding,
which may414 be a step in the extracellular deposition of Ab
after hemorrhage to form the Abþ plaques prominent in the
aging brain, may also serve to reduce the toxicity of hemoglo-
bin to central nervous tissue.412 The idea and the evidence that
each plaque forms at a site of hemorrhage from a small cerebral
vessel were developed by Cullen and colleagues.415,416
In short, as the brain evolved to greater complexity in longer
lived species such as humans, requiring greater rates of cerebral
blood flow, the risk of hemorrhage from cerebral vessels, with
their potential to spill hemoglobin into the neuropil, rose
toward inevitability. The hypoxia-induced expression of Ab
by central nervous tissue may have evolved to protect the brain
from the toxicity of the protein (hemoglobin) that evolved to
deliver oxygen to it.
Attention to the low-dose end of the relationship between
the concentration of Ab and its impact on brain tissue has thus
contributed to new understanding of the cause of age-related
dementia and of the function of the much studied, ill under-
stood Ab peptide. Ab may be not the prime driver of the
dementia (as in the amyloid cascade hypothesis) but a neuro-
protective molecule secreted by neural cells for self-protection.
We have recently220 reviewed the evidence that aging of the
vasculature (hardening of the great arteries) is the factor that
drives small-vessel hemorrhage in the aging brain, generating
the pathology reported by Alzheimer and the associated
dementia.
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Sleep Apnea, Preinfarction Angina, Prestroke Transient
Ischemic Attacks, and Peripheral Vascular Disease
It is not difficult to add to this list of paradoxes explained. The
list includes (all are reviewed above) the protective effects of
mild sleep apnea, of angina pectoris against a subsequent heart
attack, and of transient ischemic strokes against a subsequent
stroke; the long-held views that daylight and exercise and
vegetable-rich diets are “good” for us; the evidence that low-
level hunger reduces morbidity and delays mortality; the ability
of small doses of certain plant chemicals to mitigate neurode-
generations; and the ability of low-level g-rays to protect tissue
irradiated at low doses. All were surprises, counterintuitive,
“too marvelous, inviting skepticism.” It is perhaps time to put
aside the skepticism that surprise induces in us and take seri-
ously, as Calabrese400 and Mattson have pleaded,391 the broad
idea that the mammalian body has evolved mechanisms that
use everyday stress to upregulate mechanisms of tissue
resilience.
Detaching and Naming the Low-Dose-
Resilience Response
Having acknowledged the explanatory power of hormesis, we
now identify a problem. The term hormesis is used to denote, or
is defined as, a dose–response relationship, said to have a U- or
J-shape or an inverted U- or J-shape, depending on the sign
given to the ordinate, as, for example, in Figure 1 in the study
by Calabrese et al.417 The problem is that the use of such
graphs, so important in toxicology, rests on an assumption that
the change in response between low-dose stress and high-dose
stress is quantitative: more cells in the dish than in a control, or
fewer; more fibers in the muscle treated, or fewer; more occur-
rences or recurrences of cancer, or fewer.
In our view, the reality (and with it much excitement) is
that the change in tissue response with the dose of stress is
qualitative, from the upregulation of complex, evolved resi-
lience pathways at low doses to chaotic tissue destruction at
high doses. The use of a graph tends to hide the qualitative
nature of this change, which is as great as the difference
between immunity to a disease and the disease itself. We
suggest that the next step in this much-thought-about field
is to detach the low- and high-stress responses conceptually.
Put another way, the high-stress-makes-a-toxin idea was the
point of Paracelsus’ maxim—everything is toxic at some
dose. The low-stress-can-induce-resilience idea goes back to
Arndt and Schultz. They are different phenomena; they do not
belong on the same axis of a graph, though the present writers
understand why they have so often been portrayed this way.
The problem was identified by Kitchin,418 who expressed the
need to find a single mechanism to explain both low- and
high-dose responses; once it is accepted that the responses
differ qualitatively, the need for a single mechanism goes
away. And several authors, despite the above quoted defini-
tions of hormesis, have applied the name just to the low-dose
response. This field is expanding rapidly and shifts in the use
of names are a healthy sign of that growth.
This review has focused on the low-stress-resilience
response that arises, as others have suggested, from an evolved
system of stress-inducible pathways. The response evoked by
low-level stress has a name, indeed several depending on the
experimental or clinical context417; the system deserves a
name.
Choosing the Name
For the low-stress-resilience response, a valuable consensus
review of nomenclature has been provided by Calabrese and
colleagues.417 We sought a name, not for the response, but for
the underlying evolved system of cellular and molecular path-
ways, ideally a name that captures the evolutionary value of the
system to the organism. We also wanted a name that was heur-
istically open; we have explored elsewhere the heuristic issues
involved in naming biological phenomena. They are consider-
able419 and interact with understanding of scientific method.
By analogy with acquired immunity, we suggest the term
acquired resilience. Several related, novel questions can then
be asked and tested in terms of “acquired resilience,” includ-
ing—What are the phenotypes of acquired resilience? Does
acquired resilience fade with aging? Is there a phenomenon
of resiliosenescence, comparable to immunosenescence? Is
resiliosenescence part of the cause of aging? If so, can resilio-
senescence—like immunosenescence—be slowed, even
reversed? How is acquired resilience distinct from the better
known acquired immunity? In complex organisms such as
mammals, which show evidence of both acquired immunity
and acquired resilience, do the 2 systems interact? Is there a
destructive form of acquired resilience, comparable to
autoimmunity?
Below, and briefly, each of these questions is addressed.
The Phenotypes of Acquired Resilience
The phenotypes of resilience are summarized in Table 2, to
minimize repetition of material already reviewed. The pheno-
types vary with the experimental model or hypothesis of the
investigators. When investigators are interested in the healing
of a skin wound or a tooth socket, the phenotype is accelerated
healing. If their interest is in retinal degeneration, the pheno-
type is improved retinal function and structure; if in sarcopenia,
the phenotype is improved muscle strength and muscle fiber
number; if in the cellular processes of cancer, the phenotype is
prevention of the proliferation or metastasis of cancer cells; if
in the treatment of cancer, the phenotype is improved quality of
life and longer remission; if in rejuvenation, the phenotype may
be smoother, less fragile skin. The point of the summary is that
probably all tissues are capable of a resilience response and that
probably all of the stresses considered previously can elicit
each response (that has been shown only partially).
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What Happens to Acquired Resilience With Age? Is
Resiliosenescence Part of Aging?
Age-related frailty is plain in our elders; and for those of us
who have survived to be elders, then in ourselves. The evidence
that a fading of acquired resilience underlies the frailty of age is
limited but clear enough. Documented examples, already
quoted above, include the loss of the angina-induced protection
from coronary occlusion,273,275 the loss of transient-ischemia-
induced protection from stroke,278 the loss of ischemia-induced
protection of the retina,420 and the loss of caloric-restriction-
induced protection of the heart.160 It seems probable, but
strictly has yet to be shown, that all forms of resilience induc-
tion, by low-level stresses to the resilience phenotypes sum-
marized in Table 2, fade with age.
Can Resiliosenescence be Stopped?
There is evidence, already noted above, that resiliosenescence
can be slowed/stopped by exercise and caloric restriction. The
question whether other everyday stresses (hypoxia/ischemia
radiation, plant toxins) can also reverse resiliosenescence has
been less well examined. It is likely that in the near future the
question will be addressed and, for the many who reach the late
decades of human lifespan, a regime of exercise, caloric restric-
tion, and dietary supplements will emerge, to optimize these
late years. How welcome such lifestyle management can be
made remains to be seen. How much of our available energy
will be needed to keep us healthy? Will it require a month each
year on the exercise bicycle to give us another month of healthy
life? Or will the reward be substantially greater?
The problem is, of course, evolutionary. The youthful body
is organized by adaptive pressures; aging is the breakdown of
that organization. Humans, committed emotionally to delaying
death, put enormous resources into keeping healthy long past
child-bearing and child-rearing, defying our irrelevance to evo-
lution. How deep into old age will persist our willingness to
exercise, go hungry, eat bitter foods, and manage our exposure
to sunlight? Will elderly patients be able to claim that good
health as grandparents or grand-aunts and grand-uncles adds to
the success of child-rearing, thus maintaining an evolutionary
role for old? Much remains to be learned.
Do Acquired Resilience and Acquired Immunity Interact?
If 2 distinct systems of tissue maintenance are functioning in
the mammalian body, each evolved and organized, the question
can be asked—do they interact in any way? One interaction is
that both exercise and caloric restriction “hold back the clock”
on both immunosenescence and resiliosenescence. There is no
present understanding of the mechanism of this stress-induced
preservation in the aged of the ability of both the immune and
resilience systems to respond to the inducers that were once
effective in youth. Again, much remains to be understood.
Is There a Damaging Form of Acquired Resilience
(Comparable to Autoimmunity)?
Finally, we note that there appear to be few forms of resilience
that are damaging, as autoimmunity can be damaging to the
otherwise healthy organism. At the molecular level, Gargini
and colleagues421 reported that the upregulation of the growth
factor FGF-2 in retinal photoreceptors associated with stress-
induced resistance to LD also increased photoreceptor sensi-
tivity but reduced transmission of the photoreceptor response to
inner retina, resulting in a limited reduction of retinal output.
And at the psychological level (discussed above), Nelson and
colleagues260 discussed the impact of caloric restriction on the
psychology of a team isolated in the Biosphere 2 venture.
Caloric restriction and the effort of growing their food made
the team leaner and healthier but did not optimize group
dynamics for a long mission. With those exceptions, it seems
so far that activation of the pathways of acquired resilience
does not damage the function or integrity of body tissues.
Acquired Resilience, Acquired Immunity:
A Brief Comparison
It is useful, to emphasize that acquired resilience is a distinct
system of tissue protection, to compare it with acquired immu-
nity. Among the similarities, both systems are activated by an
encounter with an environmental challenge—a pathogen or a
stress; both can prevent or slow major diseases—cancer, for
example; the ability to acquire both fades with age—immuno-
senescence and resiliosenescence; and both can be maintained
into old age by the stresses that induce resilience earlier in life.
Among the differences are the inducing challenges. The
resilience response is induced by physical or metabolic stres-
ses; the immune response by biologically active pathogens.
Their mechanisms also differ. The principal mechanisms of
acquired immunity are humoral (the production of antibodies
to a foreign antigen) and cellular (the proliferation of killer
lymphocytes to kill cells carrying a foreign antigen). The
mechanisms of acquired resilience include the mobilization
of bone marrow–derived cells that enhance the healing of
wounds, the absorption of infrared light to upregulate mito-
chondrial function in damaged cells, and the release of trophic
cytokines by ischemic muscle. Further, acquired immunity is
much more specific. Although there is some evidence of cross-
immunity (dairy maids do not get smallpox—the founding
observation of acquired immunity), vaccination against polio
is specific to polio, and vaccination against this winter’s ‘flu
may not work against next winter’s. By contrast, the resilience
induced by exercise, intermittent hunger, hypoxia, plant toxins,
and radiation affects the whole organism, in a range of pheno-
types. And finally, as just noted, there is only limited evidence
of a phenomenon of “autoresilience,” analogous to autoimmu-
nity. Resilience mechanisms act to stabilize the structure and
preserve the function of the tissues of the host animal, while the
mechanisms of immunity are those of counterattack, aimed at
foreign antigens, killing pathogen-infected cells, but capable of
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running out of control and killing healthy cells, even the whole
animal. That difference between defense (resilience) and coun-
terattack (immunity) is perhaps the fundamental difference
between the 2 systems, both evolved to protect the organism.
Summary and Conclusions
This review proposes the recognition of an evolved system of
cellular mechanisms in mammals that underlies the low-dose-
resilience response—the ability of organisms to use everyday
stresses as stimuli to upregulate endogenous mechanisms that
increase the resilience of tissues. We suggest terming this
evolved system “acquired resilience,” by analogy with
acquired immunity. Acquired resilience is distinctive in that
its cellular mechanisms are not (like those of acquired immu-
nity) mechanisms of attack, countering invading pathogens
very specifically but capable of exceeding their targets and
destroying the host animal (autoimmunity). The mechanisms
of resilience appear to be ones of pure defense; as a conse-
quence, there is little evidence of a phenomenon of autoresi-
lience, comparable to autoimmunity. One feature common to
acquired immunity and acquired resilience is that both fade
with age and that both can be extended into old age by every-
day stresses such as exercise and caloric restriction, and per-
haps more. This extension is the basis of long-accepted but
partly understood views that moderate exercise and certain
“healthy” diets are “good for us,” decreasing morbidity in the
aging human and delaying mortality.
Understanding of acquired resilience, and of the parameters
of the low-stress-resilience response that underlies it, is already
providing therapeutic tools for medical conditions as serious as
heart attack, stroke, and the age-related neurodegenerations
(including dementia, parkinsonism, and macular degeneration).
Much remains to be learned, but the outlines of the system, and
its emergence through ideas of dose–response relationships and
hormesis, so from the work of Paracelsus during the Renais-
sance, to Arndt and Schulz in the 19th century, to more recent
investigators such as Southam last century and Calabrese and
Mattson in this century, can now be discerned. It seems likely
to become a reference point in many aspects of medicine, from
prescribing a healthy diet to the management of cancer to
understanding what is required for healthy aging.
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Note
1. How long have we believed exercise to be good for us? Even if we
ignore ancient treatises, then at least 2 centuries: Jane Austen used
the term “healthful” in Pride and Prejudice (1813, Chapter 28):
“To work in the garden was one of his (Charlotte’s vexing husband
Mr Collins’) most respectable pleasures; and Elizabeth admired the
command of countenance with which Charlotte talked of the
healthfulness of the exercise, and owned she encouraged it as much
as possible.” The phrase to take a “constitutional” walk also dates
to the early 19th century (1829, according to Merriam Webster’s
Dictionary).
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